{"id":5032,"date":"2018-12-13T22:00:00","date_gmt":"2018-12-13T22:00:00","guid":{"rendered":"https:\/\/www.millicozum.com\/mc\/2018\/12\/13\/asilarla-saglik-mi-yoksa-hastalik-mi-asilaniyor\/"},"modified":"2018-12-13T22:00:00","modified_gmt":"2018-12-13T22:00:00","slug":"asilarla-saglik-mi-yoksa-hastalik-mi-asilaniyor","status":"publish","type":"post","link":"https:\/\/www.millicozum.com\/mc\/ozel-yazilar\/asilarla-saglik-mi-yoksa-hastalik-mi-asilaniyor\/","title":{"rendered":"\u201cA\u015eI\u201dLARLA; SA\u011eLIK MI, YOKSA HASTALIK MI A\u015eILANIYOR?"},"content":{"rendered":"\n<p>&nbsp;<\/p>\n<p><!-- [if gte mso 9]><xml>  <o:OfficeDocumentSettings>   <o:RelyOnVML\/>   <o:AllowPNG\/>  <\/o:OfficeDocumentSettings> <\/xml><![endif]--><!-- [if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal<\/w:View>   <w:Zoom>0<\/w:Zoom>   <w:TrackMoves\/>   <w:TrackFormatting\/>   <w:DoNotShowComments\/>   <w:DoNotShowPropertyChanges\/>   <w:HyphenationZone>21<\/w:HyphenationZone>   <w:PunctuationKerning\/>   <w:ValidateAgainstSchemas\/>   <w:SaveIfXMLInvalid>false<\/w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false<\/w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false<\/w:AlwaysShowPlaceholderText>   <w:DoNotPromoteQF\/>   <w:LidThemeOther>TR<\/w:LidThemeOther>   <w:LidThemeAsian>X-NONE<\/w:LidThemeAsian>   <w:LidThemeComplexScript>X-NONE<\/w:LidThemeComplexScript>   <w:Compatibility>    <w:BreakWrappedTables\/>    <w:SnapToGridInCell\/>    <w:WrapTextWithPunct\/>    <w:UseAsianBreakRules\/>    <w:DontGrowAutofit\/>    <w:SplitPgBreakAndParaMark\/>    <w:EnableOpenTypeKerning\/>    <w:DontFlipMirrorIndents\/>    <w:OverrideTableStyleHps\/>    <w:UseFELayout\/>   <\/w:Compatibility>   <m:mathPr>    <m:mathFont m:val=\"Cambria Math\"\/>    <m:brkBin m:val=\"before\"\/>    <m:brkBinSub m:val=\"&#45;-\"\/>    <m:smallFrac m:val=\"off\"\/>    <m:dispDef\/>    <m:lMargin m:val=\"0\"\/>    <m:rMargin m:val=\"0\"\/>    <m:defJc m:val=\"centerGroup\"\/>    <m:wrapIndent m:val=\"1440\"\/>    <m:intLim m:val=\"subSup\"\/>    <m:naryLim m:val=\"undOvr\"\/>   <\/m:mathPr><\/w:WordDocument> <\/xml><![endif]--><!-- [if gte mso 9]><xml>  <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"   DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"   LatentStyleCount=\"375\">   <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 7\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 8\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 9\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 7\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 8\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 9\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Normal Indent\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"footnote text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"annotation text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"header\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"footer\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index heading\"\/>   <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"table of figures\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"envelope address\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"envelope return\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"footnote reference\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"annotation reference\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"line number\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"page number\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"endnote reference\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"endnote text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"table of authorities\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"macro\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"toa heading\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Closing\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Signature\"\/>   <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text Indent\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Message Header\"\/>   <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Salutation\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Date\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text First Indent\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text First Indent 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Note Heading\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text Indent 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text Indent 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Block Text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Hyperlink\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"FollowedHyperlink\"\/>   <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"\/>   <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Document Map\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Plain Text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"E-mail Signature\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Top of Form\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Bottom of Form\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Normal (Web)\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Acronym\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Address\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Cite\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Code\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Definition\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Keyboard\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Preformatted\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Sample\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Typewriter\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Variable\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Normal Table\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"annotation subject\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"No List\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Outline List 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Outline List 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Outline List 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Simple 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Simple 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Simple 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Colorful 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Colorful 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Colorful 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 7\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 8\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 7\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 8\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table 3D effects 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table 3D effects 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table 3D effects 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Contemporary\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Elegant\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Professional\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Subtle 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Subtle 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Web 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Web 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Web 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Balloon Text\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Theme\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"\/>   <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"\/>   <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"    Name=\"List Paragraph\"\/>   <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"\/>   <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"    Name=\"Intense Quote\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"    Name=\"Subtle Emphasis\"\/>   <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"    Name=\"Intense Emphasis\"\/>   <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"    Name=\"Subtle Reference\"\/>   <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"    Name=\"Intense Reference\"\/>   <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"\/>   <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"Bibliography\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"\/>   <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Mention\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Smart Hyperlink\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Hashtag\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Unresolved Mention\"\/>  <\/w:LatentStyles> <\/xml><![endif]--><!-- [if gte mso 10]>  <![endif]--><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: .0001pt; text-align: center;\" align=\"center\"><strong style=\"font-size: 18pt;\"><span style=\"font-size: 20pt; line-height: 115%; font-family: Arial, sans-serif;\">&ldquo;A\u015eI&rdquo;LARLA; SA\u011eLIK MI,<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: center;\"><span style=\"font-size: 18pt;\"><strong><span style=\"font-size: 20pt; line-height: 115%; font-family: Arial, sans-serif;\">YOKSA HASTALIK MI A\u015eILANIYOR?<\/span><\/strong><\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: center;\"><strong><span style=\"font-size: 20pt; line-height: 115%; font-family: Arial, sans-serif;\"> &nbsp;&nbsp;&nbsp;&nbsp; <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bir hastal\u0131\u011fa kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flamak veya bu hastal\u0131\u011f\u0131 tedavi etmek i&ccedil;in haz\u0131rlanan ve v&uuml;cuda kas, damar veya a\u011f\u0131z yoluyla verilen s\u0131v\u0131ya a\u015f\u0131 ismi verilir. A\u015f\u0131, zay\u0131flatma ad\u0131 verilen uygun bir sterilizasyonla hastal\u0131k yapma g&uuml;c&uuml; yok edilen bir mikrop maddesinden meydana gelmektedir.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">A\u015f\u0131n\u0131n yararlar\u0131 nelerdir?<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Uygun ve do\u011fru a\u015f\u0131lar\u0131n sa\u011flad\u0131\u011f\u0131 en b&uuml;y&uuml;k yarar toplum sa\u011fl\u0131\u011f\u0131n\u0131n devam ettirilmesidir. A\u015f\u0131lar &ouml;ncelikle uyguland\u0131klar\u0131 ki\u015fileri hastal\u0131ktan korur, ancak hastal\u0131ktan korunan ki\u015filer mikroplar\u0131 di\u011fer ki\u015filere ta\u015f\u0131yamayaca\u011f\u0131ndan ve a\u015f\u0131lanmam\u0131\u015f ki\u015filere de hastal\u0131\u011f\u0131n ge&ccedil;i\u015fi engellenece\u011fi i&ccedil;in onlar da korunabilir. <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Enfeksiyon hastal\u0131klar\u0131n\u0131n yaratt\u0131\u011f\u0131 bireysel hasar ve maliyet yan\u0131nda k\u0131sa s&uuml;rede b&uuml;y&uuml;k kitlelere ula\u015fmas\u0131 sonucu olu\u015fturdu\u011fu etki &ccedil;ok daha tehlikelidir. Hastal\u0131\u011f\u0131n olu\u015fmas\u0131n\u0131 &ouml;nlemek her zaman tedavi etmekten &ccedil;ok daha kolay ve g&uuml;venilirdir. Hastal\u0131klar zaman zaman hi&ccedil;bir \u015fekilde tedavi edilemeyecek sorunlara ve kal\u0131c\u0131 hasarlara yol a&ccedil;abilmektedirler.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Evet; canl\u0131larda hastal\u0131k nedeni olabilecek mikroplar\u0131n &ouml;zel i\u015flemlerden ge&ccedil;irilmesi sonucu, <strong><em>hastal\u0131k yap\u0131c\u0131 etkileri yok edilmi\u015f, ancak v&uuml;cudun savunma (ba\u011f\u0131\u015f\u0131kl\u0131k) sistemini uyaracak nitelikleri korunmu\u015f <\/em><\/strong>t\u0131bbi &uuml;r&uuml;nlere a\u015f\u0131 denir. Mikroplar\u0131n v&uuml;cuda girip hastal\u0131k yapmalar\u0131na <\/span><em><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\"><strong>&#8216;Enfeksiyon&#8217;<\/strong> <\/span><\/em><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">denir. V&uuml;cuda yabanc\u0131 olup da v&uuml;cutta kar\u015f\u0131 reaksiyon uyand\u0131ran maddelere <\/span><em><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">&#8216;Antijen&#8217; <\/span><\/em><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">denir. V&uuml;cutta yabanc\u0131 maddeye kar\u015f\u0131 ortaya &ccedil;\u0131kan savunma maddelerine <\/span><em><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">&#8216;Antikor&#8217; <\/span><\/em><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">denmektedir. Ba\u015fta h&uuml;cre &ccedil;eperleri olmak &uuml;zere mikroplar\u0131n &ccedil;e\u015fitli yap\u0131lar\u0131 v&uuml;cut i&ccedil;in kuvvetli birer antijendir. Bir&ccedil;ok enfeksiyon hastal\u0131\u011f\u0131nda, hastal\u0131\u011f\u0131 ge&ccedil;irdikten sonra, ki\u015fide, o hastal\u0131klara kar\u015f\u0131 bir dayan\u0131kl\u0131l\u0131k durumu (Ba\u011f\u0131\u015f\u0131kl\u0131k) meydana gelir. O halde, bu hastal\u0131klara kar\u015f\u0131 sun&#8217;i tedbirlerle ki\u015filere ba\u011f\u0131\u015f\u0131kl\u0131k kazand\u0131rmak m&uuml;mk&uuml;n ve m&uuml;nasiptir. Ancak do\u011fru ve uygun olmayan A\u015eI&rsquo;lar tam aksine daha b&uuml;y&uuml;k hasarlara yol a&ccedil;abilmektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">\u0130ki t&uuml;rl&uuml; ba\u011f\u0131\u015f\u0131kl\u0131k bilinmektedir:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1. Aktif Ba\u011f\u0131\u015f\u0131kl\u0131k:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Antijen verilir. V&uuml;cut kendi gayretleriyle antijene kar\u015f\u0131 savunma maddelerini, yani antikorlar\u0131n\u0131 haz\u0131rlamaya giri\u015fir. <strong>2. Pasif Ba\u011f\u0131\u015f\u0131kl\u0131k:<\/strong> Ba\u015fka canl\u0131da, o mikroba kar\u015f\u0131 meydana getirilmi\u015f antikorlar (gamma glabunli serum) verilir. <\/span><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Tesiri &ccedil;ok &ccedil;abuk ba\u015flar, ama birka&ccedil; hafta gibi &ccedil;ok k\u0131sa bir zaman devam eder.<\/span><span style=\"font-size: 12pt;\"> <\/span><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Aktif ba\u011f\u0131\u015f\u0131klamada ise (a\u015f\u0131lama ile) ba\u011f\u0131\u015f\u0131kl\u0131k s&uuml;resi y\u0131llarla &ouml;l&ccedil;&uuml;lebilir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Yayg\u0131n Olarak Kullan\u0131lan A\u015f\u0131lar<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Difteri A\u015f\u0131s\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Bu mikrop, toksinin zarars\u0131z hale getirilmesiyle yap\u0131l\u0131r. Koruma de\u011feri %95&rsquo;tir. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bo\u011fmaca A\u015f\u0131s\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> &Ouml;l&uuml; bo\u011fmaca bakterisinden elde edilen bakteri a\u015f\u0131s\u0131d\u0131r. Koruma de\u011feri %85&rsquo;tir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Tetanos A\u015f\u0131s\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Tetanos mikrobunun toksininin zarars\u0131z hale getirilmesiyle yap\u0131l\u0131r. Difteri, bo\u011fmaca ve tetanos a\u015f\u0131lar\u0131 karma a\u015f\u0131 olarak (DBT) bir arada yap\u0131labilir. Koruma de\u011feri %100&rsquo;d&uuml;r. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Ccedil;ocuk Felci:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> &Ccedil;ocuk felci vir&uuml;s&uuml;n&uuml;n etkisiz hale getirilmesiyle elde edilen bir canl\u0131 vir&uuml;s a\u015f\u0131s\u0131d\u0131r. Koruma de\u011feri %85-%90 oldu\u011fu s&ouml;ylenir. Ancak son zamanlarda baz\u0131 a\u015f\u0131lar\u0131n &ccedil;ocuklarda kal\u0131c\u0131 hastal\u0131k ve hasarlara yol a&ccedil;t\u0131\u011f\u0131 tespit edilmi\u015ftir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">K\u0131zam\u0131k A\u015f\u0131s\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Canl\u0131 vir&uuml;s a\u015f\u0131s\u0131d\u0131r. &Uuml;st kola, kas i&ccedil;ine 0.5 ml uygulan\u0131r. A\u015f\u0131dan 7-10 g&uuml;n sonra ate\u015f, g&ouml;z nezlesi, d&ouml;k&uuml;nt&uuml; olabilir. Koruma de\u011feri %95&rsquo;tir. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Kabakulak A\u015f\u0131s\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Canl\u0131 vir&uuml;s a\u015f\u0131s\u0131d\u0131r. 1 ya\u015f\u0131ndan sonra yap\u0131l\u0131r. K\u0131zam\u0131k, k\u0131zam\u0131k&ccedil;\u0131k ve kabakulak bir arada yap\u0131labilir. &Uuml;lkemizde yayg\u0131n olarak kullan\u0131lmamaktad\u0131r. Koruma de\u011feri %95&rsquo;tir. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">B-C-G A\u015f\u0131s\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Verem hastal\u0131\u011f\u0131na kar\u015f\u0131l\u0131k kullan\u0131lan bir canl\u0131 bakteri a\u015f\u0131s\u0131d\u0131r. Sol omza deri i&ccedil;ine 0.1 ml yap\u0131l\u0131r. Yeni do\u011fan &ccedil;ocuklara ilk ay i&ccedil;inde yap\u0131l\u0131r. \u0130leri ya\u015flarda t&uuml;berk&uuml;lin (PPD) testi, menfi ise yap\u0131l\u0131r. A\u015f\u0131ya ba\u011fl\u0131 deri alt\u0131 apsesi, lenf bezi \u015fi\u015fmesi g&ouml;r&uuml;lebilir. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Kuduz A\u015f\u0131s\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Canl\u0131 vir&uuml;s a\u015f\u0131s\u0131d\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Bu konulara &ouml;zel ilgi duyan ve ciddi ara\u015ft\u0131rmalar yapan bir yazar\u0131m\u0131z &ccedil;ok &ccedil;arp\u0131c\u0131 sonu&ccedil;lara ula\u015fm\u0131\u015ft\u0131: A\u015f\u0131lar &ccedil;ocuklara otizm ve zihinsel hastal\u0131klar bula\u015ft\u0131r\u0131yordu!<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><em><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&ldquo;Ani bebek &ouml;l&uuml;mlerinin y&uuml;zde 70&prime;i Difteri, Tetanos, Bo\u011fmaca a\u015f\u0131s\u0131n\u0131 takip eden 3 hafta i&ccedil;inde ger&ccedil;ekle\u015fmektedir. Havalelerin a\u015f\u0131larla ba\u011flant\u0131l\u0131 oldu\u011fu tespit edilmi\u015ftir; havalenin a\u015f\u0131 olduktan hemen sonra olmas\u0131 da gerekmemektedir. Haftalar, aylar, hatta bir y\u0131l sonra bile ger&ccedil;ekle\u015febilir.&rdquo;<\/span><\/em><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">E\u011fer ba\u011f\u0131\u015f\u0131kl\u0131k sistemini uyar\u0131rsan, bug&uuml;n otizmin &ccedil;\u0131kt\u0131\u011f\u0131 gibi, hamileyken a\u015f\u0131lad\u0131\u011f\u0131n kad\u0131n\u0131n &ccedil;ocu\u011fu 20 y\u0131l sonra \u015fizofreni &ccedil;\u0131kabilecektir. Bu a\u015f\u0131lar\u0131n &ccedil;o\u011fu &Ccedil;in&#8217;de &uuml;retilmektedir. AB ve ABD&rsquo;de 2 y\u0131lda bir kontrol edilirken &Ccedil;in&#8217;de ise 13 y\u0131lda bir kontrol edilmektedir.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Canl\u0131 vir&uuml;s i&ccedil;eren a\u015f\u0131lar\u0131n tehlikeleri:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; A\u015f\u0131lar ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 bast\u0131r\u0131yor. (KKK ve HIB)<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Hayat boyunca v&uuml;cutta kalabiliyor. K\u0131zam\u0131k vir&uuml;s&uuml; ya\u015fl\u0131lar\u0131n %20 beyin ve %45 di\u011fer dokular\u0131nda rastlan\u0131yor.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Ast\u0131m, &ccedil;ocuklarda \u015feker hastal\u0131\u011f\u0131 ve otoimmun ve n&ouml;rolojik hastal\u0131klarla ba\u011flant\u0131l\u0131 ortaya &ccedil;\u0131k\u0131yor.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; 1970&prime;ten sonra her &ccedil;ocuk felci vakas\u0131n\u0131n oral &ccedil;ocuk felci a\u015f\u0131s\u0131 kaynakl\u0131 oldu\u011fu ortaya &ccedil;\u0131km\u0131\u015f bulunuyor.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Nijerya&rsquo;da &ccedil;ocuk felci salg\u0131n\u0131n\u0131n oral &ccedil;ocuk felci a\u015f\u0131s\u0131yla ortaya &ccedil;\u0131kt\u0131\u011f\u0131 saptand\u0131. \u015eimdi etraf\u0131ndaki &uuml;lkelere &ldquo;Nijerya&rsquo;da &ccedil;ocuk felci salg\u0131n\u0131 var, a\u015f\u0131 olmazlarsa size bula\u015ft\u0131racaklar&rdquo; diye propaganda yap\u0131ld\u0131. Bunun &uuml;zerine kom\u015fular\u0131 Nijerya&rsquo;y\u0131 sava\u015fla tehdit etmeye ba\u015flad\u0131. Nijerya&rsquo;da a\u015f\u0131 yapt\u0131rmayanlar\u0131 hapse att\u0131lar. Oysa ABD&rsquo;de canl\u0131 &ccedil;ocuk felci a\u015f\u0131s\u0131 yasakt\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">En zararl\u0131 a\u015f\u0131 hangisidir?<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hepatit B a\u015f\u0131s\u0131 &uuml;retilmi\u015f sinir sistemini mahveden en zararl\u0131 a\u015f\u0131d\u0131r. Ben &ccedil;ocuklu\u011fumda b&uuml;t&uuml;n hastal\u0131klara yakalan\u0131p atlatt\u0131m, ama etraf\u0131mda, s\u0131n\u0131f\u0131mda bu hastal\u0131klardan sorun ya\u015fayan hi&ccedil; kimseye rastlamad\u0131m. E\u011fer dedikleri gibi bu kadar &ouml;l&uuml;mc&uuml;l olsayd\u0131, benim zaman\u0131mda a\u015f\u0131lar\u0131 yoktu, sokaklar &ouml;l&uuml;lerle dolu olacakt\u0131. Hastal\u0131\u011f\u0131 ge&ccedil;irdi\u011finde &ouml;m&uuml;r boyu ba\u011f\u0131\u015f\u0131kl\u0131k kazan\u0131l\u0131r. Oysa a\u015f\u0131 olunca 4 y\u0131l a\u015f\u0131n\u0131n korumad\u0131\u011f\u0131n\u0131 anlad\u0131klar\u0131nda bu sefer de peki\u015ftirme dozlar vurmaya ba\u015flan\u0131r. <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">K\u0131zam\u0131k a\u015f\u0131s\u0131ndan &ouml;nce k\u0131zam\u0131k &ouml;l&uuml;mleri d&uuml;\u015fme e\u011filimindeydi<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">K\u0131zam\u0131k a\u015f\u0131s\u0131 ba\u015flamadan &ouml;nce k\u0131zam\u0131ktan &ouml;l&uuml;m vakalar\u0131 y&uuml;zde 90 zaten azalm\u0131\u015ft\u0131. Hijyen, iyi beslenme, iyi bak\u0131m laz\u0131md\u0131. K\u0131zam\u0131k a\u015f\u0131s\u0131 sonucunda da &ouml;l&uuml;m oranlar\u0131 artm\u0131\u015ft\u0131. Ve fark ettiler ki a\u015f\u0131dan sonra &ccedil;ocuklar &Ccedil;inko ve A vitamini yoksunlu\u011fu &ccedil;ekiyordu. Bunlar verildi\u011finde &ouml;l&uuml;m oranlar\u0131 yine d&uuml;\u015fmeye ba\u015flam\u0131\u015ft\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">&Ccedil;ocuk felci zaten sorun de\u011fildi<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Ccedil;ocuk felci salg\u0131n\u0131 DTB a\u015f\u0131s\u0131 ba\u015flayana kadar sorun te\u015fkil etmemi\u015fti. &Ccedil;ocuk felci her daim vard\u0131. Ama hi&ccedil;bir d&ouml;nemde DTB a\u015f\u0131n\u0131n ba\u015flamas\u0131yla ba\u015flayan d&ouml;nem gibi bir d&ouml;nem ya\u015fanmam\u0131\u015ft\u0131. Birdenbire felce ve &ouml;l&uuml;me neden olmas\u0131 herkesi \u015fa\u015f\u0131rtm\u0131\u015ft\u0131. &Ccedil;&uuml;nk&uuml; o zamana kadar yaz gribi gibiydi.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Grip a\u015f\u0131s\u0131 &ouml;l&uuml;mleri tetikledi<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">2003 y\u0131l\u0131nda &ccedil;ocuklara grip a\u015f\u0131s\u0131n\u0131n vurulmas\u0131na ba\u015fland\u0131ktan sonra 5 ya\u015f alt\u0131 gripten &ouml;len &ccedil;ocuklar\u0131n rakam\u0131 12&prime;den 90&rsquo;a &ccedil;\u0131kt\u0131. 2 ya\u015f &uuml;st&uuml; grip a\u015f\u0131s\u0131 canl\u0131 grip a\u015f\u0131s\u0131 y&uuml;zde 33 etkili, zay\u0131flat\u0131lm\u0131\u015f grip a\u015f\u0131s\u0131 y&uuml;zde 36 etkili. 2 ya\u015f alt\u0131 zay\u0131flat\u0131lm\u0131\u015f grip a\u015f\u0131s\u0131 y&uuml;zde 0 etkili. Ama gel g&ouml;r ki \u015fimdi her ya\u015fa vurulmas\u0131 &ouml;neriliyor.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Peki, ya doktorlar ve sa\u011fl\u0131k &ccedil;al\u0131\u015fanlar\u0131 bu a\u015f\u0131y\u0131 oluyorlar m\u0131yd\u0131?<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bat\u0131 &uuml;lkelerindeki doktor ve hem\u015firelerin y&uuml;zde 70&prime;i a\u015f\u0131 olmaya &ldquo;hay\u0131r&rdquo; demi\u015ftir. Sa\u011fl\u0131k &ccedil;al\u0131\u015fanlar\u0131n\u0131n ise y&uuml;zde 62&rsquo;si &ldquo;hay\u0131r&rdquo; demi\u015ftir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Tetanos a\u015f\u0131s\u0131 g&ouml;rd&uuml;\u011f&uuml;m en komik a\u015f\u0131yd\u0131<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Tetanos kapma olas\u0131l\u0131\u011f\u0131n\u0131z, yolda bana &ccedil;arpma olas\u0131l\u0131\u011f\u0131n\u0131z kadar az. Kald\u0131 ki \u015fu anda camdan eli kesilmi\u015flere bile Tetanos a\u015f\u0131s\u0131 vurulmaktayd\u0131. Tetanos oksijensiz ortamda ya\u015fayabilir. Bu nedenle oksijenli suyla temizlik yap\u0131l\u0131r. Tetanos hayvanlar\u0131n d\u0131\u015fk\u0131s\u0131n\u0131n oldu\u011fu yerde ya\u015far. Evinizde cam k\u0131r\u0131\u011f\u0131ndan Tetanos kapamazs\u0131n\u0131z. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">K\u0131zam\u0131ktan &ouml;l&uuml;mlerde ate\u015f d&uuml;\u015f&uuml;r&uuml;c&uuml;lerin rol&uuml;&hellip;<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> E\u011fer bundan endi\u015fe ediyorsan\u0131z ate\u015f d&uuml;\u015f&uuml;r&uuml;c&uuml; vermeyiniz. Ate\u015f d&uuml;\u015f&uuml;r&uuml;c&uuml;lerin etkisiyle &ouml;l&uuml;m oran\u0131 y&uuml;zde 7&prime;den y&uuml;zde 35&prime;e y&uuml;kselmi\u015f. B\u0131rak\u0131n ate\u015f y&uuml;kselsin, 40-41&prime;i ge&ccedil;medik&ccedil;e sorun de\u011fil. B&ouml;ylece k\u0131zam\u0131ktan &ouml;l&uuml;mleri ciddi oranda d&uuml;\u015f&uuml;rm&uuml;\u015f olursunuz.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1984 k\u0131zam\u0131k salg\u0131n\u0131: &ccedil;ocuklar\u0131m\u0131z\u0131n %58&rsquo;i a\u015f\u0131l\u0131yd\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1985 k\u0131zam\u0131k salg\u0131n\u0131: &ccedil;ocuklar\u0131m\u0131z\u0131n %99&rsquo;u a\u015f\u0131l\u0131yd\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1986 k\u0131zam\u0131k salg\u0131n\u0131: &ccedil;ocuklar\u0131m\u0131z\u0131n %96&rsquo;s\u0131 a\u015f\u0131l\u0131yd\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1988 k\u0131zam\u0131k salg\u0131n\u0131: &ccedil;ocuklar\u0131m\u0131z\u0131n %69&rsquo;u a\u015f\u0131l\u0131yd\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1989 k\u0131zam\u0131k salg\u0131n\u0131: &ccedil;ocuklar\u0131m\u0131z\u0131n %89&rsquo;u a\u015f\u0131l\u0131yd\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1995 k\u0131zam\u0131k salg\u0131n\u0131: &ccedil;ocuklar\u0131m\u0131z\u0131n %56&rsquo;s\u0131 a\u015f\u0131l\u0131yd\u0131. Ama maalesef s&ouml;ylenen ve istenen faydalar sa\u011flanamam\u0131\u015ft\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">K\u0131zam\u0131k&ccedil;\u0131k a\u015f\u0131s\u0131 %55 kad\u0131nda eklem iltihaplanmas\u0131na neden oluyordu. Doktorlar\u0131n %75&prime;i k\u0131zam\u0131k&ccedil;\u0131k a\u015f\u0131s\u0131 olmay\u0131 reddediyordu. Kad\u0131n hastal\u0131klar\u0131 ve do\u011fum uzmanlar\u0131n\u0131n ise y&uuml;zde 91&prime;i reddediyordu. Hepatit B de en komik a\u015f\u0131lardan biri. Vaka say\u0131s\u0131 25-64 ya\u015f grubunda 4.172 iken 0-4 ya\u015f aral\u0131\u011f\u0131nda 5&rsquo;ti. E\u011fer y&uuml;ksek risk ta\u015f\u0131yan bir anneye sahip de\u011filse bebek 18 ya\u015f\u0131na kadar Hepatit vir&uuml;s&uuml;yle kar\u015f\u0131la\u015fma olas\u0131l\u0131\u011f\u0131 neredeyse hi&ccedil; yoktu. Di\u011fer konu, Hepatit B a\u015f\u0131s\u0131n\u0131n koruyuculu\u011fu 2 y\u0131ld\u0131. Yani do\u011fumdan sonra vurulan Hepatit B a\u015f\u0131s\u0131n\u0131n, 18 ya\u015f\u0131na gelindi\u011finde hi&ccedil;bir etkisi kalm\u0131yordu.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">A\u015fa\u011f\u0131da; CDC&#8217;nin yay\u0131mlad\u0131\u011f\u0131 a\u015f\u0131 i&ccedil;erik listesinden derlenmi\u015f k\u0131smi a\u015f\u0131 i&ccedil;eri\u011fi listesi ile yine a\u015f\u0131 &uuml;reticisinin kendi yay\u0131nlar\u0131nda (prospekt&uuml;slerinde) belirtti\u011fi yan etkileri g&ouml;steren liste verilmektedir:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-family: Arial, sans-serif;\"><\/span><\/strong><\/p>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr style=\"height: 21.45pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 21.45pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; text-align: center; line-height: 10pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">A\u015f\u0131lar<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; text-align: center; line-height: 10pt;\"><span class=\"Gvdemetni2\"><strong><span style=\"font-family: Arial, sans-serif;\">(&ccedil;e\u015fitli &uuml;reticilerden)<\/span><\/strong><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 21.45pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-align: center; text-indent: 0.85pt; line-height: 10pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">\u0130&ccedil;indekiler<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-align: center; text-indent: 0.85pt; line-height: 10pt;\"><span class=\"Gvdemetni2\"><strong><span style=\"font-family: Arial, sans-serif;\">(k\u0131smi listedir)<\/span><\/strong><\/span><\/p>\n<\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 21.45pt;\" valign=\"top\" width=\"223\">\n<p style=\"margin-top: 0cm; margin-right: 6.95pt; margin-bottom: 0.0001pt; text-align: center; text-indent: 2.1pt; line-height: 10pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Yan Etkileri<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 6.95pt; margin-bottom: 0.0001pt; text-align: center; text-indent: 2.1pt; line-height: 10pt;\"><span class=\"Gvdemetni2\"><strong><span style=\"font-family: Arial, sans-serif;\">(k\u0131smi listedir)<\/span><\/strong><\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 84.8pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 84.8pt;\" valign=\"top\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">DtaB <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">(Difteri, Tetanoz, asel&uuml;ler Bo\u011fmaca) <\/span><\/span><span class=\"Gvdemetni2\"><strong><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">A\u015f\u0131s\u0131<\/span><\/strong><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, adsorbe<\/span><\/span><\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 84.8pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-indent: 0.85pt; line-height: 11.3pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Al&uuml;minyum fosfat<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\"><strong>,<\/strong> amonyum s&uuml;lfat, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Al&uuml;minyum <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">potasyum s&uuml;lfat, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\"><strong>Thimerosal<\/strong> <\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">[a\u011f\u0131rl\u0131\u011f\u0131n\u0131n %50&#8217;si <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">c\u0131va <\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">olan bir a\u015f\u0131 koruyucusu], Formaldehid veya Formalin, Glutaraldehye, <\/span><\/span><\/p>\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-indent: 0.85pt; line-height: 11.3pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">2- Phoenoxyethanol<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\"><strong>,<\/strong> Dimethyl- betacyclodextrin, Sodium Phosphate, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Polysorbate 80<\/span><\/span><\/p>\n<\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 84.8pt;\" valign=\"top\" width=\"223\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Otizm<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">, ate\u015f, anoreksiya, kusma, zat&uuml;rre, menenjit, sepsis, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">bo\u011fmaca<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">, konv&uuml;lsiyon, febril, gran mal, afebril ve k\u0131smi n&ouml;bet\/havale, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\"><strong>ensefalopati<\/strong> [<\/span><\/span><span style=\"font-family: Arial, sans-serif;\">beyin <\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">dokusunda genelde dejeneratif de\u011fi\u015fikliklerin g&ouml;r&uuml;ld&uuml;\u011f&uuml; hastal\u0131klara verilen isim], <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">brakiyel nevrit<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Guillain-Barre sendromu, Ani Bebek &Ouml;l&uuml;m&uuml; Sendromu<\/span><\/span><\/strong><\/td>\n<\/tr>\n<tr style=\"height: 107.1pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 107.1pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">DTaB\/HepB\/IPV Kombine A\u015f\u0131s\u0131<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">,<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Difteri ve Tetanoz Toksoidleri ile Asel&uuml;ler Bo\u011fmaca Adsorbe\/ Hepatit B (Rekombinant) ve \u0130naktive Polio vir&uuml;s&uuml; (&ccedil;ocuk felci) A\u015f\u0131s\u0131 Kombine<\/span><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 107.1pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-indent: 0.85pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Al&uuml;minyum Hidroksit, Al&uuml;minyum Fosfat, Formaldehid <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">veya Formalin, Glutaraldehid, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Maymun B&ouml;bre\u011fi Dokusu<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>,<\/strong> Neomycin [antibiyotik], <\/span><\/span><\/p>\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-indent: 0.85pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">2- Phenoxyethanol<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>,<\/strong> Polymyxin B, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Polysorbate 80<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>,<\/strong> Antibiyotikler, Maya Proteini.<\/span><\/span><\/p>\n<\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 107.1pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Havale\/n&ouml;bet, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">diabet<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">ast\u0131m<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>,<\/strong> <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Ani Bebek &Ouml;l&uuml;m&uuml; Sendromu<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>,<\/strong> &uuml;st solunum yollar\u0131 enfeksiyonu, anormal karaci\u011fer fonksiyonu testleri, anoreksiya, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">sar\u0131l\u0131k<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">\u015fok<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">,<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"> <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">ensefalopati, Stevens-Johnson sendromu, brakiyel nevrit<\/span><\/span><\/strong><\/td>\n<\/tr>\n<tr style=\"height: 78.25pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 78.25pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; line-height: 10pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Grip A\u015f\u0131s\u0131<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; line-height: 10pt;\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Influenza Vir&uuml;s&uuml; A\u015f\u0131s\u0131<\/span><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 78.25pt;\" valign=\"top\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Thimerosal <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">[c\u0131va], Civciv B&ouml;bre\u011fi H&uuml;creleri, Yumurta Proteini, Gentamisin S&uuml;lfat, Antibiyotikler, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>Monosodyum Glutamat [MSG],<\/strong> <\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Sukroz Fosfat\u0131 Glutamat Tamponu.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 78.25pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Ciddi solunum ve mide-barsak semptomlar\u0131, havale\/n&ouml;bet, alerjik ast\u0131m, i\u015ftah kayb\u0131, mitokondriyal ensefalomiyopatide art\u0131\u015f, k\u0131smi y&uuml;z felci, Guillain-Barre sendromu, Bell&#8217;s palsy, Stevens-Johnson sendromu, herpes zoster [zona].<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 107.5pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 107.5pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; line-height: 10pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Hep B A\u015f\u0131s\u0131<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; line-height: 10pt;\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Hepatit B A\u015f\u0131s\u0131<\/span><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 107.5pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-indent: 0.85pt; line-height: 11.3pt;\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Al&uuml;minyum Hidroksifosfat S&uuml;lfat\u0131, Amino Asitler, Dekstroz, Fosfat Tamponlar\u0131, Potasyum Al&uuml;minyum S&uuml;lfat, Formaldehid veya Formalin, Mineral Tuzlar\u0131, Soya Peptonu, Maya Proteini, Thimerosal [2007 y\u0131l\u0131ndan &ouml;nce T&uuml;rkiye&#8217;de de kullan\u0131lan ve do\u011fumda vurulan Engerix B<\/span><\/span><\/p>\n<p style=\"margin-top: 0cm; margin-right: 5.25pt; margin-bottom: 0.0001pt; text-indent: 0.85pt; line-height: 11.3pt;\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">(GlaxoSmithKline Biologicals) a\u015f\u0131s\u0131 Thimerosal ihtiva ediyordu]<\/span><\/span><\/p>\n<\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 107.5pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Influenza, febril konv&uuml;ls&uuml;yon, anoreksiya, &uuml;st solunum yollar\u0131 hastal\u0131klar\u0131, herpes zoster [zona], <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\"><strong>ansefalit<\/strong> <\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">[beyin iltihab\u0131], palpitasyonlar, artrit, sistemik <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">lupus <\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">ertematosus (SLE), konj&uuml;nktivit, anormal karaci\u011fer enzim de\u011ferleri, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Guillain-Barre sendromu, Bell&#8217;s palsy<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">multipl skleroz<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">anafilaksi<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\"><strong>,<\/strong> havale\/n&ouml;betler.<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 36.8pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 36.8pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; line-height: 11.3pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">HIB A\u015f\u0131s\u0131<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt; line-height: 11.3pt;\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Haemophilus b Konj&uuml;ge A\u015f\u0131s\u0131 (Tetanoz Toksoidi Konj&uuml;ge)<\/span><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 36.8pt;\" valign=\"top\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Amonyum s&uuml;lfat, Formaldehid veya Formalin, Sukroz.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 36.8pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Anoreksiya, havale\/n&ouml;bet, <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">b&ouml;brek yetmezli\u011fi<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\"><strong>,<\/strong> Guillain-Barre Sendromu (GBS), ishal, kusma.<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 61.55pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 61.55pt;\" valign=\"top\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">HIB\/HepB A\u015f\u0131s\u0131<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>,<\/strong> (Rekombinant) Haemophilus b Konj&uuml;ge (Menengokok Protein Konj&uuml;ge) ve Hep B<\/span><\/span><\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 61.55pt;\" valign=\"top\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Al&uuml;minyum Hidroksifosfat S&uuml;lfat, Formaldehid veya Formalin, Sodyum Borat, Soya Peptonu, Maya proteini, Amino asitler, Dekstroz, Mineral Tuzlar\u0131.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 61.55pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Anoreksiya, havale, otitis media [kulak enfeksiyonu], &uuml;st solunum yollar\u0131 enfeksiyonu, oral candida [mantar enfeksiyonu], anafilaksi [\u015fok].<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 40.4pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 40.4pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">HIB \/ Meningokok <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">[Haemophilus b Konjuge <\/span><\/span><span class=\"Gvdemetni2\"><strong><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">A\u015f\u0131s\u0131<\/span><\/strong><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"> (Meningokok Protein Konjuge)]<\/span><\/span><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 40.4pt;\" valign=\"top\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Al&uuml;minyum Hidroksifosfat S&uuml;lfat\u0131, Formaldehid veya Formalin, Posfat Tamponlar\u0131.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 40.4pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Febril konv&uuml;lsiyonlar, HIB hastal\u0131\u011f\u0131 ba\u015flang\u0131c\u0131, otitis media [kulak enfeksiyonu], &uuml;st solunum yollar\u0131 enfeksiyonu, Guillain-Barre sendromu<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 63.7pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 63.7pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">KKK A\u015f\u0131s\u0131<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">,<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">K\u0131zam\u0131k, Kabakulak, K\u0131zam\u0131k&ccedil;\u0131k Vir&uuml;s A\u015f\u0131s\u0131, Canl\u0131<\/span><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 63.7pt;\" valign=\"top\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Civciv Embriyosu <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Fibroblastlar\u0131, Amino Asitler, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>S\u0131\u011f\u0131r Albumini<\/strong> <\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">veya Serumu [kan\u0131n s\u0131v\u0131 k\u0131sm\u0131], <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">\u0130nsan Serum Alb&uuml;mini<\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, Antibiyotikler, Glutamat, Fosfat Tamponlar\u0131, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Jelatin<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, Sorbitol, Sukroz, Vitaminler.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 63.7pt;\" valign=\"top\" width=\"223\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Atipik k\u0131zam\u0131k<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">artrit<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, <\/span><\/span><\/strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"><strong>ansefalit<\/strong> [beyin iltihab\u0131]<\/span><\/span><span class=\"Gvdemetni2\"><strong><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">,<\/span><\/strong><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"> <\/span><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">&ouml;l&uuml;m<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">, <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">aseptik menenjit<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">,<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\"> <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">otitis media <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">[kulak enfeksiyonu].<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 41.3pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 41.3pt;\" valign=\"top\">\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Pn&ouml;mokok<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">,<\/span><\/span><\/strong><\/p>\n<p style=\"margin-top: 0cm; margin-right: 2.85pt; margin-bottom: 0.0001pt;\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Pn&ouml;mokok 7-Valanl\u0131 Konj&uuml;ge A\u015f\u0131 (Difteri CRM197 Proteini)<\/span><\/span><\/p>\n<\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 41.3pt;\" valign=\"top\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Al&uuml;minyum Fosfat, Maya Ekstrat\u0131, Amino Asitler, Soya Peptonu.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 41.3pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Febril konv&uuml;lsiyon, Ani Bebek &Ouml;l&uuml;m&uuml;, anafilaktik \u015fok, i\u015ftah kayb\u0131,<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 56.85pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 56.85pt;\" valign=\"top\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">Polio vir&uuml;s&uuml; A\u015f\u0131s\u0131 (IPV) <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"line-height: 115%; font-family: Arial, sans-serif;\">\u0130naktive &Ccedil;ocuk Felci Vir&uuml;s&uuml; A\u015f\u0131s\u0131<\/span><\/span><\/td>\n<td style=\"border-top: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; border-right: none; background: white; padding: 0cm 0.5pt; height: 56.85pt;\" valign=\"top\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">2-Phenoxyethanol, Formaldehid veya Formalin, Maymun B&ouml;bre\u011fi Dokusu, Yenido\u011fmu\u015f Buza\u011f\u0131 Serum Proteini, Antibiyotikler Neomycin, Polymyxin B, Streptomycin.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; border-top: 1pt solid windowtext; border-right: 1pt solid windowtext; border-left: 1pt solid windowtext; border-bottom: none; background: white; padding: 0cm 0.5pt; height: 56.85pt;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">&Ouml;l&uuml;m, anoreksiya, Guillain-Barre sendromu.<\/span><\/span><\/td>\n<\/tr>\n<tr style=\"height: 91.7pt;\">\n<td style=\"border-top: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-right: none; background: white; padding: 0cm 0.5pt; height: 91.7pt;\" valign=\"top\"><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">Su &Ccedil;i&ccedil;e\u011fi <\/span><\/span><\/strong><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">(Varicella) <\/span><\/span><span class=\"Gvdemetni2\"><strong><span style=\"font-family: Arial, sans-serif;\">Vir&uuml;s <\/span><\/strong><\/span><strong><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\">A\u015f\u0131s\u0131<\/span><\/span><\/strong><\/td>\n<td style=\"border-top: 1pt solid windowtext; border-bottom: 1pt solid windowtext; border-left: 1pt solid windowtext; border-right: none; background: white; padding: 0cm 0.5pt; height: 91.7pt;\" valign=\"top\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Ethylenediamine-Tetraacetic Acid Sodium (EDTA) [metal &ccedil;&ouml;zme\/\u015felasyon ajan\u0131], S\u0131\u011f\u0131r albumini veya serumu, antibiyotikler, Monosodyum glutamat [MSG], <\/span><\/span><span class=\"Gvdemetni2Kaln\"><span style=\"font-family: Arial, sans-serif;\"><strong>MRC-5 DNA ve H&uuml;cre Protein<\/strong>i<\/span><\/span><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">, Neomycin, Potasyum Klor&uuml;r, Potasyum Fosfat Monobasic, Sodyum Fosfat Monobasic, Sukroz.<\/span><\/span><\/td>\n<td style=\"width: 167.2pt; background: white; padding: 0cm 0.5pt; height: 91.7pt; border: 1pt solid windowtext;\" valign=\"top\" width=\"223\"><span class=\"Gvdemetni2\"><span style=\"font-family: Arial, sans-serif;\">Febril konv&uuml;lsiyon, ansefalit [beyin iltihab\u0131], Varicella-benzeri d&ouml;k&uuml;nt&uuml;, &uuml;st solunum yollar\u0131 rahats\u0131zl\u0131\u011f\u0131, alt solunum yollar\u0131 rahats\u0131zl\u0131\u011f\u0131, egzama, y&uuml;z &ouml;demi, aft ve u&ccedil;uk, aseptik menenjit, Guillain-Barre Sendromu, Bell&#8217;s palsy, zat&uuml;rre, sekonder bakteriyel enfeksiyonlar.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">B&uuml;t&uuml;n bu ac\u0131 ve gelece\u011fimizi karart\u0131c\u0131 ger&ccedil;ekleri g&ouml;rd&uuml;kten sonra, tek ve ger&ccedil;ek &ccedil;arenin, kendi milli ve yerli a\u015f\u0131lar\u0131m\u0131z\u0131 ve di\u011fer b&uuml;t&uuml;n ila&ccedil;lar\u0131m\u0131z\u0131 &uuml;retmemiz gerekti\u011fi ortaya &ccedil;\u0131k\u0131yordu. Ama maalesef AKP iktidar\u0131 bu konuda 16 y\u0131l boyunca ciddi ve ger&ccedil;ek&ccedil;i hi&ccedil;bir ad\u0131m atm\u0131yor, bizi Bat\u0131l\u0131 ve Siyonist ortakl\u0131 k&uuml;resel firmalara mahk&ucirc;m ve mecbur ediyordu.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Dr. Sherri Tenpenny&rsquo;nin a\u015f\u0131 ara\u015ft\u0131rmalar\u0131 neyi g&ouml;stermi\u015fti?<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">O d&ouml;nem yarat\u0131lan panikle H1N1 a\u015f\u0131s\u0131n\u0131 olmak i&ccedil;in 2-3 saat s\u0131ralarda bekleyen halk\u0131n durumundan etkilenerek konuya ba\u015fl\u0131yordu. Dr. Tenpenny 2000 y\u0131l\u0131n\u0131n Eyl&uuml;l&rsquo;&uuml;nde Washington&rsquo;da d&uuml;zenlenen NVIC-National Vaccine Information Centre toplant\u0131s\u0131na kat\u0131l\u0131yor, eve d&ouml;nd&uuml;\u011f&uuml;nde kendi kendine \u015f&ouml;yle d&uuml;\u015f&uuml;n&uuml;yordu: <strong><em>&ldquo;Vay can\u0131na, 1985&rsquo;ten beri hekimlik yap\u0131yorum, 1996&rsquo;dan beri &lsquo;B&uuml;t&uuml;nleyici T\u0131p&rsquo; icra ediyorum, \u015fimdi sene olmu\u015f 2000, bu a\u015f\u0131 meselesini nas\u0131l ka&ccedil;\u0131rm\u0131\u015f olabilirim?!&rdquo;<\/em><\/strong><\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bunun nedenini 3 nesil Kayropraktik uygulay\u0131c\u0131s\u0131 olan bir aileden geliyor olmas\u0131 ve kendi ailesinden kimsenin o g&uuml;ne kadar a\u015f\u0131 yapt\u0131rmam\u0131\u015f olmas\u0131; kendi &ccedil;ocu\u011fu da olmad\u0131\u011f\u0131ndan a\u015f\u0131 konusunun g&uuml;ndemine gelmemesi ve o g&uuml;ne kadar a\u015f\u0131dan zarar g&ouml;rm&uuml;\u015f biriyle kar\u015f\u0131la\u015fmam\u0131\u015f olmas\u0131na ba\u011fl\u0131yordu. Konu ilgisini &ccedil;ekiyor ve 3 g&uuml;n s&uuml;ren toplant\u0131lara kat\u0131l\u0131yor. 3 g&uuml;n boyunca &ccedil;ocu\u011fu a\u015f\u0131dan zarar g&ouml;rm&uuml;\u015f ebeveynlerin ifadelerinin yan\u0131s\u0131ra &ccedil;ok say\u0131da bilim adam\u0131 ve hekimin a\u015f\u0131lar\u0131n zararlar\u0131n\u0131 anlatt\u0131\u011f\u0131 konu\u015fmalar\u0131 dinleyince, yine bunca \u015feyden kendisinin niye o g&uuml;ne kadar haberdar olmad\u0131\u011f\u0131na \u015fa\u015f\u0131yordu. &Ouml;yle olunca da, <em>&ldquo;ben bu konuya bir bakay\u0131m bakal\u0131m&rdquo; <\/em>diye d&uuml;\u015f&uuml;n&uuml;yordu. Okudu\u011fu ilk makale, (CDC) Centres for Disease Control&rsquo;un kendi sitesinden General Recommendations on Vaccination adl\u0131 bilgilendirme yaz\u0131s\u0131n\u0131n 1998&rsquo;deki versiyonu oluyordu. 42 sayfal\u0131k makalenin sonuna geldi\u011finde tepkisi: <strong><em>&ldquo;Bu mudur?!&rdquo;<\/em><\/strong> (Sa\u011fl\u0131\u011f\u0131 koruma ad\u0131na yap\u0131lan bu uygulamalar, asl\u0131nda insan sa\u011fl\u0131\u011f\u0131n\u0131 tehdit ediyordu!..) <em>&ldquo;Koca a\u015f\u0131 end&uuml;strisi bundan m\u0131 ibaret yani&rdquo;<\/em> diye \u015fa\u015f\u0131r\u0131yor, &ccedil;&uuml;nk&uuml; g&ouml;rd&uuml;\u011f&uuml; \u015fey hatal\u0131 birtak\u0131m bilimsel &ccedil;al\u0131\u015fmalara dayanarak yap\u0131lm\u0131\u015f yalan yanl\u0131\u015f &ccedil;\u0131kar\u0131mlar\u0131n bol miktarda hipotez ve varsay\u0131mla s&uuml;slenmi\u015f hali ve birka&ccedil; da yaz\u0131m yanl\u0131\u015f\u0131 ve dil bilgisi hatas\u0131yla doluydu. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><em><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&ldquo;Hakikaten bu muymu\u015f yani?! Milyar dolarl\u0131k end&uuml;strinin dayana\u011f\u0131 bu muymu\u015f?!&rdquo;<\/span><\/em><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> diye hayretler i&ccedil;inde kal\u0131yor ve <strong><em>&ldquo;ben bunu biraz daha ara\u015ft\u0131ray\u0131m bakal\u0131m&rdquo;<\/em><\/strong> demek zorunda kal\u0131yordu. Biraz ara\u015ft\u0131rmak i&ccedil;in &ccedil;\u0131kt\u0131\u011f\u0131 yol, 11 sene boyunca 12,000 saatlik okuma ve ara\u015ft\u0131rma maratonuna d&ouml;n&uuml;\u015f&uuml;yordu. Sonunda <strong><em>&ldquo;Aramad\u0131\u011f\u0131n\u0131z \u015feyi bulamazs\u0131n\u0131z&rdquo;<\/em><\/strong> diyordu. Dr. Tenpenny. <strong><em>&ldquo;E\u011fer arad\u0131\u011f\u0131n\u0131z bir \u015fey varsa, ancak bulup a&ccedil;\u0131\u011fa &ccedil;\u0131kartman\u0131z m&uuml;mk&uuml;n olabilir.&rdquo;<\/em><\/strong> diyordu.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Dr. Sherri Tenpenny onca y\u0131ll\u0131k ara\u015ft\u0131rmalar\u0131nda \u015fu sonu&ccedil;lara varm\u0131\u015ft\u0131:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Kimilerinin &ldquo;palavradan bilim&rdquo; de dedi\u011fi bir s&uuml;r&uuml; k&ouml;t&uuml; icra edilmi\u015f uyduruk bilim safsatalar\u0131.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Bilimseldir diye ortaya konmu\u015f bir dolu tekinsiz, \u015fi\u015firme, yalan yanl\u0131\u015f ara\u015ft\u0131rma sonu&ccedil;lar\u0131.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; &Ccedil;al\u0131\u015fma &Ouml;zeti&rsquo;nin alt\u0131nda yer alan &lsquo;Sonu&ccedil;&rsquo; b&ouml;l&uuml;m&uuml;nde yap\u0131lan &ccedil;\u0131kar\u0131mlar\u0131n, &ccedil;al\u0131\u015fman\u0131n geri kalan\u0131nda anlat\u0131lan hi&ccedil;bir \u015feyle alakas\u0131n\u0131n dahi olmad\u0131\u011f\u0131 &ldquo;bilimsel&rdquo; k\u0131l\u0131fl\u0131 beyin y\u0131kama &ccedil;al\u0131\u015fmalar\u0131.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&ldquo;A\u015f\u0131ya ba\u011fl\u0131 bunca problemin neden kaynaklanabilece\u011fini g&ouml;steren yaz\u0131l\u0131 belge, kan\u0131t var m\u0131?&rdquo; diye de bak\u0131yordu bir yandan Dr. Tenpenny ve bunun i&ccedil;in t\u0131p literat&uuml;r&uuml;ne ge&ccedil;mi\u015f, yay\u0131mlanm\u0131\u015f &ccedil;al\u0131\u015fmalardan a\u015f\u0131 yan etkilerini ara\u015ft\u0131r\u0131yor ve aralar\u0131ndan sadece birka&ccedil;\u0131n\u0131 say\u0131veriyordu:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Otoimm&uuml;n hastal\u0131klar.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Lupus:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> &Uuml;lserle\u015fme e\u011filimi g&ouml;steren lezyonlarla belirgin herhangi bir kronik deri hastal\u0131\u011f\u0131, &ouml;zellikle lupus eritematozus ya da lupus vulgaris.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; ITP &#8211; \u0130dyopatik Trombositopenik Purpura:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Kan\u0131n normal p\u0131ht\u0131la\u015fmas\u0131n\u0131n bozuldu\u011fu ve kanamaya meyille giden bir hastal\u0131kt\u0131r. Kanamaya yatk\u0131nl\u0131\u011f\u0131n nedeni, kan\u0131n p\u0131ht\u0131la\u015fmas\u0131ndan sorumlu kan pulcuklar\u0131ndaki (trombosit=plt=platelet) azalmad\u0131r. ITP&rsquo;de kan pulcuklar\u0131ndaki azalman\u0131n nedeni v&uuml;cudun kendi &uuml;retti\u011fi kan pulcuklar\u0131n\u0131 yok etmeye ba\u015flamas\u0131d\u0131r. ITP bula\u015f\u0131c\u0131 ya da genetik bir hastal\u0131k de\u011fildir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Tiroidit -Tiroid bezi iltihab\u0131.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; &Uuml;rtiker ve d&ouml;k&uuml;nt&uuml;.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Reaktif Artrit &#8211; Reiter Sendromu:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Son bir ay i&ccedil;inde veya h&acirc;lihaz\u0131rda bir enfeksiyona tepki olarak geli\u015fen inflamatuar artrit \u015feklidir. Ge&ccedil;mi\u015fte, &ldquo;Reiter sendromu&rdquo; ad\u0131 verilirdi; ancak \u015fimdilerde &ldquo;spondiloartrit&rdquo; ailesinin bir &uuml;yesi olarak kabul edilmektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Reaktif artrit:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> &Ouml;zellikle diz veya ayak bilekleri gibi eklemleri, topuklar, parmaklar ve beli etkileyebilir. Reaktif artrit, genellikle ishal ya da cinsel yolla bula\u015fan bir hastal\u0131ktan sonra g&ouml;r&uuml;l&uuml;r. Ancak hemen her enfeksiyona reaksiyon olarak da geli\u015febilir. Bazen enfeksiyona ait belirti olmadan da &lsquo;asemptomatik&rsquo; geli\u015febilir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; J&uuml;venil kronik artrit:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Her 1000 &ccedil;ocuktan birinde g&ouml;r&uuml;len nadir(!) bir iltihapl\u0131 romatizmal hastal\u0131k. Eklemlerden herhangi biri aylarca inflame kald\u0131\u011f\u0131 ve ba\u015fka bir neden bulunamad\u0131\u011f\u0131 zaman, kronik artritten \u015f&uuml;phe edilebilir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; N&ouml;betler:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Hastal\u0131k n&ouml;beti; &ouml;zellikle aniden geli\u015fen konv&uuml;lsiyonlarla belirgin n&ouml;bet.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; MS &#8211; Multipl Skleroz:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Beyin ve omurilikte, sinir aksonlar\u0131ndaki miyelin kayb\u0131na ba\u011fl\u0131 olarak yer yer sertle\u015fmi\u015f b&ouml;lgeler olu\u015fmas\u0131 ile belirgin, optik nevrit, bacak kaslar\u0131nda g&uuml;&ccedil; kayb\u0131, istemli hareketlerde d&uuml;zensizlik, ba\u015f d&ouml;nmesi ve di\u011fer sinirsel bozukluklarla seyreden merkezi sinir sistemi hastal\u0131\u011f\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; MS benzeri sendromlar.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Santral sinir sistemi demiyelinasyonu.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Polin&ouml;ropati: <\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Birka&ccedil; siniri ilgilendiren herhangi bir hastal\u0131k veya bozukluk; &ouml;zellikle bir&ccedil;ok sinirin -iltihaplanma olmaks\u0131z\u0131n- dejeneratif de\u011fi\u015fiklikler g&ouml;stermesi.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Tip 1 Diyabet:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> \u0130ns&uuml;line Ba\u011f\u0131ml\u0131 Diyabet. Pankreas&rsquo;tan yeterli ins&uuml;lin salg\u0131lanmamas\u0131 sonucu geli\u015fen \u015feker hastal\u0131\u011f\u0131 \u015fekli.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Vask&uuml;lit:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Damar iltihab\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; &Ccedil;ok &ccedil;e\u015fitli vask&uuml;ler hastal\u0131klar\/damar hastal\u0131klar\u0131.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Bilateral Optik Nevrit:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> G&ouml;z siniri iltihab\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Santral Retinal Arter Okl&uuml;zyonu:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> K&ouml;rl&uuml;\u011fe g&ouml;t&uuml;r&uuml;r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; \u0130\u015fitme kayb\u0131.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Tam sa\u011f\u0131rl\u0131k.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Nefrotik Sendrom:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> B&ouml;brek glomer&uuml;llerindeki i\u015flev bozuklu\u011fu sonucu geli\u015fen, yayg\u0131n &ouml;dem, a\u011f\u0131r proteinim, hipoalb&uuml;minemi ve hiperlipemi ile belirgin klinik tablo.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Ast\u0131m<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Egzama<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&bull; Otizm<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"><\/span><\/strong><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Dr. Tenpenny&rsquo;nin sayd\u0131\u011f\u0131 bu k\u0131smi(!) hastal\u0131k listesi sadece Hepatit-B a\u015f\u0131s\u0131 sonras\u0131 geli\u015fenlerden olu\u015fuyordu!<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Peki, ama ya onca di\u011fer a\u015f\u0131lar ve onlar\u0131n yaratt\u0131\u011f\u0131 di\u011fer sa\u011fl\u0131k sorunlar\u0131 neler olmaktayd\u0131?<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Dr. Tenpenny bu durumu;<em> &ldquo;A\u015f\u0131 End&uuml;strisi, k&uuml;resel \u0130la&ccedil; End&uuml;strisi&rsquo;nin belkemi\u011fidir&rdquo;<\/em><\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> diye a&ccedil;\u0131kl\u0131yordu. <strong><em>&ldquo;B&uuml;t&uuml;n &ccedil;ocuklara do\u011fumda Hepatit-B a\u015f\u0131s\u0131 yap\u0131ld\u0131\u011f\u0131n\u0131 ve bu &ccedil;ocuklar\u0131n uzay\u0131p giden bu listeler dolusu hastal\u0131klar\u0131 geli\u015ftirdi\u011fini d&uuml;\u015f&uuml;nelim. Acaba &ccedil;o\u011fu &ouml;m&uuml;r boyu s&uuml;recek bu sorunlar i&ccedil;in ka&ccedil; milyon ila&ccedil; sat\u0131lacak dersiniz? Ka&ccedil; tetkik, ka&ccedil; test, ka&ccedil; hastane yat\u0131\u015f\u0131 demek bu? Hem de salt TEK bir a\u015f\u0131dan dolay\u0131 olu\u015fabilecek yan etkilerden bahsediyoruz. Do\u011fum an\u0131ndan ba\u015flay\u0131p hayat boyu devam eden bir a\u015f\u0131lanma s&uuml;recinden bahsediyoruz burada. End&uuml;striyi i\u015fte kelimenin tam manas\u0131yla b&ouml;yle ayakta tutuyor a\u015f\u0131lar.&rdquo;<\/em><\/strong> diyordu ve son tespiti ise \u015f&ouml;yle oluyordu: <strong><em>&ldquo;A\u015f\u0131lamay\u0131 sadece yar\u0131 yar\u0131ya kessek, mevcut sa\u011fl\u0131k sekt&ouml;r&uuml;n&uuml;n spektrumu tamam\u0131yla de\u011fi\u015fecektir.&rdquo;<\/em><\/strong><\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Hepatit B a\u015f\u0131s\u0131 ve geli\u015fim bozukluklar\u0131<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">2008 y\u0131l\u0131nda Gallagher ve Goodman taraf\u0131ndan bir ara\u015ft\u0131rma yap\u0131lm\u0131\u015ft\u0131r. Ara\u015ft\u0131rma Hepatit B 3&rsquo;l&uuml; seri a\u015f\u0131 ile geli\u015fim bozuklu\u011fu aras\u0131ndaki ili\u015fki &uuml;zerine yo\u011funla\u015fm\u0131\u015ft\u0131r. Ara\u015ft\u0131rma yap\u0131lan &ccedil;ocuk say\u0131s\u0131 1824, ya\u015f aral\u0131\u011f\u0131 ise 1 ila 9 aras\u0131d\u0131r. Tiyormersal i&ccedil;eren Hepatit B 3&rsquo;l&uuml; serinin a\u015f\u0131s\u0131n\u0131 olan &ldquo;erkek&rdquo; &ccedil;ocuklar\u0131n, a\u015f\u0131lanmayan &ccedil;ocuklara oranla geli\u015fim bozukluklar\u0131na daha yatk\u0131n olduklar\u0131 saptanm\u0131\u015ft\u0131r. Tamamen a\u015f\u0131lanm\u0131\u015f erkek &ccedil;ocuklar\u0131n &ouml;zel e\u011fitim hizmeti alma say\u0131s\u0131, a\u015f\u0131lanmayan erkek &ccedil;ocuklar\u0131n 8.63 kat\u0131 fazlayd\u0131. Bu ara\u015ft\u0131rma Amerika Birle\u015fik Devletleri&rsquo;nde yap\u0131lm\u0131\u015ft\u0131r. Ayn\u0131 yazarlar\u0131n di\u011fer ara\u015ft\u0131rmas\u0131 yeni do\u011fmu\u015f erkek bebeklere yap\u0131lan Hep B a\u015f\u0131s\u0131yla otizm te\u015fhisi aras\u0131ndaki ili\u015fki &uuml;zerine yap\u0131lm\u0131\u015ft\u0131r. Ara\u015ft\u0131rma yap\u0131lan erkek &ccedil;ocuklar otizm te\u015fhisi konmu\u015f, 1999 y\u0131l\u0131 &ouml;ncesi do\u011fmu\u015f 3 ila 17 ya\u015f aral\u0131\u011f\u0131ndaki &ccedil;ocuklard\u0131r. 1999 &ouml;ncesi do\u011fan ve Hep B a\u015f\u0131s\u0131 olanlar\u0131n otizme yakalanmalar\u0131 3 kat fazlayd\u0131. (Gallagher CM, Goodman MS, &ldquo;hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002, J Toxicol Environ Health, Part A, 73 (2010): 1665-1667)[1]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Hepatit B A\u015f\u0131s\u0131 ve sonu&ccedil;lar\u0131<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Maalesef doktorlara Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131&rsquo;n\u0131n g&ouml;nderdi\u011fi tebli\u011fler, anne-babalara yapt\u0131rd\u0131klar\u0131 a&ccedil;\u0131klamalar do\u011frudan Amerikan CDC kurumunun &ccedil;arp\u0131t\u0131lm\u0131\u015f, tarafl\u0131 ve bilimsel olarak da kusurlu a&ccedil;\u0131klamalar\u0131d\u0131r. Amerikan takvimini h\u0131zla kopya ediyoruz, anne-babalar\u0131 &ldquo;ikna&rdquo; (korkutma) ve y\u0131ld\u0131rma taktikleri de do\u011frudan bu &uuml;lkeden ithal edildi\u011fi toplumdan saklanmaktad\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">T&uuml;rkiye&rsquo;de Hepatit B hastal\u0131\u011f\u0131n\u0131n &ccedil;ocuk ya\u015f grubundaki riski ile ilgili yapt\u0131\u011f\u0131m ara\u015ft\u0131rman\u0131n sonu&ccedil;lar\u0131n\u0131 ve Hepatit B hastal\u0131\u011f\u0131 ile ilgili referansl\u0131 bilgilerden bir k\u0131sm\u0131n\u0131 buradan payla\u015fay\u0131m sizinle, siz bu bilgileri l&uuml;tfen doktorunuzla ayr\u0131ca payla\u015f\u0131n.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Hepatit B hastal\u0131\u011f\u0131n\u0131n ger&ccedil;ek risk oranlar\u0131:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hastal\u0131\u011f\u0131 kapanlar\u0131n %50&prime;si belirti geli\u015ftirmez; iyile\u015ferek &ouml;m&uuml;r boyu ba\u011f\u0131\u015f\u0131kl\u0131k kazan\u0131r (bu ki\u015filer hastal\u0131\u011f\u0131 ge&ccedil;irdi\u011fini bile fark etmez),<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hastal\u0131\u011f\u0131 kapanlar\u0131n %30&prime;u sadece grip benzeri belirtilerle hastal\u0131\u011f\u0131 atlat\u0131r; &ouml;m&uuml;r boyu ba\u011f\u0131\u015f\u0131kl\u0131k kazan\u0131r,<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hastal\u0131\u011f\u0131 kapanlar\u0131n %20&prime;si Hepatit B tan\u0131s\u0131 almalar\u0131na neden olacak belirtileri (bulant\u0131, kusma, sar\u0131l\u0131k, artm\u0131\u015f karaci\u011fer enzim de\u011ferleri) g&ouml;sterir, yani kendini doktora gidecek kadar hasta hisseder,<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Belirti geli\u015ftiren bu %20&prime;lik kesimin %95&lsquo;i hastal\u0131ktan tamamen iyile\u015fir; &ouml;m&uuml;r boyu ba\u011f\u0131\u015f\u0131kl\u0131k kazan\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Sonu&ccedil; olarak, Hepatit B ge&ccedil;irmi\u015f ki\u015filerin yaln\u0131zca %5&prime;ten az bir b&ouml;l&uuml;m&uuml; hastal\u0131k rezervuar\u0131 olarak adland\u0131r\u0131labilecek duruma, yani kronik ta\u015f\u0131y\u0131c\u0131l\u0131k durumuna ge&ccedil;er. Bunlar\u0131n ise, %75&prime;i (toplam Hepatit B&rsquo;li hastalar\u0131n %3.75&prime;i) asemptomatik (inaktif) enfeksiyonla ya\u015famlar\u0131n\u0131 s&uuml;rd&uuml;r&uuml;r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">%25&prime;i (toplam Hepatit B&rsquo;li hastalar\u0131n %1.25&lsquo;i) karaci\u011fer rahats\u0131zl\u0131\u011f\u0131 ve kanser geli\u015ftirir; bu rahats\u0131zl\u0131klar ise akut epizoddan 10 ila 30 sene sonra ba\u015f g&ouml;stermektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hepatit B Bula\u015fma Yollar\u0131:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1. Parenteral (kan ve kan &uuml;r&uuml;nleri aktar\u0131m\u0131 ve damardan uyu\u015fturucu kullan\u0131m\u0131 s\u0131ras\u0131nda).<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">2. Perinatal (do\u011fum s&uuml;recinde, HBV ta\u015f\u0131y\u0131c\u0131s\u0131 anneden bebe\u011fe vertikal\/dikey ge&ccedil;i\u015f yoluyla; y&uuml;ksek endemite g&ouml;r&uuml;len b&ouml;lgelerde daha s\u0131k rastlan\u0131r. T&uuml;rkiye&rsquo;de HBV i&ccedil;in &ouml;nemli bir bula\u015f yolu olmad\u0131\u011f\u0131 g&ouml;sterilmi\u015ftir).<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">3. Cinsel<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">4. Horizontal (g&ouml;sterilebilir parenteral, cinsel veya perinatal temas olmamas\u0131na kar\u015f\u0131n meydana gelen, insandan insana zedelenmi\u015f deri ya da mukoza arac\u0131l\u0131\u011f\u0131yla ve ortak kullan\u0131m alanlar\u0131 nedeniyle meydana geldi\u011fi d&uuml;\u015f&uuml;n&uuml;len bula\u015f \u015fekli).<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Dedenin ta\u015f\u0131y\u0131c\u0131 oldu\u011funu s&ouml;ylemi\u015fsiniz, ancak hangi deneyimli doktora sorsan\u0131z size Hep-B&rsquo;nin &ouml;yle sar\u0131lma &ouml;pmeyle bula\u015fmayaca\u011f\u0131n\u0131, &ccedil;ocu\u011fun cildinde mevcut a&ccedil;\u0131k bir yara varsa ve enfekte ki\u015fiyle uzun temas sonucu kan\u0131, salyas\u0131 yaraya gelirse kapaca\u011f\u0131n\u0131 belirtecektir. T&uuml;rkiye&rsquo;de &ccedil;ocuk grubunda ne kadar vaka var diye bakacak olursak da \u015f&ouml;yle bir tablo &ccedil;\u0131k\u0131yor kar\u015f\u0131m\u0131za:<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&ldquo;Prof. Dr. Hilal &Ouml;zcebe&rsquo;nin edit&ouml;rl&uuml;\u011f&uuml;nde haz\u0131rlanm\u0131\u015f, &ldquo;T&uuml;rkiye&rsquo;de &Ccedil;ocuk Sa\u011fl\u0131\u011f\u0131n\u0131n Durumu&rdquo; adl\u0131 raporda TC. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Temel Sa\u011fl\u0131k Hizmetleri Ba\u011f\u0131\u015f\u0131klama \u015eubesi&rsquo;nin bas\u0131lmam\u0131\u015f verilerine g&ouml;re Hepatit B&rsquo;nin T&uuml;rkiye&rsquo;de 5 ya\u015f alt\u0131 &ccedil;ocuklarda g&ouml;r&uuml;lme oran\u0131 2010 y\u0131l\u0131nda y&uuml;z binde 0,5&rsquo;tir (yani milyonda 5 &ccedil;ocuk). Yani, bir daha alt\u0131 &ccedil;izilerek ifade etmek gerekirse, T&uuml;rkiye&rsquo;de 0-5 ya\u015f aras\u0131 bebek ve &ccedil;ocuklarda Hepatit B bir halk sa\u011fl\u0131\u011f\u0131 &ouml;nceli\u011fi de\u011fildir ve yeni do\u011fanlar\u0131n ulusal &ccedil;apta a\u015f\u0131lanmas\u0131n\u0131 gerektirmemektedir!&rdquo;<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Polio (&ccedil;ocuk felci) a\u015f\u0131s\u0131 ve ku\u015fkular\u0131m\u0131z<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Polio enfeksiyonlar\u0131n\u0131n &ccedil;o\u011funda ancak birka&ccedil; belirgin semptom ortaya &ccedil;\u0131k\u0131yor.[2]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\">&nbsp;<strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hatta esas\u0131na bak\u0131lacak olursa, do\u011fal polio vir&uuml;s&uuml;ne maruz kalan ki\u015filerin %95&rsquo;i salg\u0131n durumunda bile(!) hi&ccedil;bir belirti g&ouml;stermiyor.[3]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Enfekte ki\u015filerin sadece %5&rsquo;inde hafif belirtiler, yani bo\u011faz a\u011fr\u0131s\u0131, boyun tutuklu\u011fu, ba\u015f a\u011fr\u0131s\u0131 ve ate\u015f gibi belirtiler g&ouml;r&uuml;l&uuml;yor ki bu da &ccedil;o\u011fu kez basit bir so\u011fuk alg\u0131nl\u0131\u011f\u0131 veya grip te\u015fhisi olabiliyor.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Kas paralizisinin hastal\u0131\u011fa yakalanm\u0131\u015f her 1.000 ki\u015fide 1 gibi bir oranda seyretti\u011fi tahmin ediliyor.[4]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bu durum baz\u0131 ara\u015ft\u0131rmac\u0131 bilim adamlar\u0131na &lsquo;paralitik polio&rsquo; (fel&ccedil;) geli\u015ftiren bu az say\u0131da insanda hastal\u0131\u011fa anatomik yatk\u0131nl\u0131k olabilece\u011fini, n&uuml;fusun geri kalan ezici &ccedil;o\u011funlu\u011funun ise polio vir&uuml;s&uuml;ne do\u011fal olarak ba\u011f\u0131\u015f\u0131k olabilece\u011fini d&uuml;\u015f&uuml;nd&uuml;r&uuml;yor.[5]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Paralitik polio nadiren kal\u0131c\u0131, &uuml;stelik &ccedil;o\u011fu kez fel&ccedil;ten TAM iyile\u015fme sa\u011flan\u0131yor.[6]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Birka&ccedil; g&uuml;n i&ccedil;inde kas g&uuml;c&uuml; yerine gelmeye ba\u015fl\u0131yor ve sonraki 12-24 ay i&ccedil;inde iyile\u015fme devam ediyor.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Vakalar\u0131n &ccedil;ok d&uuml;\u015f&uuml;k bir y&uuml;zdesinde paralizi kal\u0131nt\u0131s\u0131 g&ouml;r&uuml;l&uuml;yor.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Ccedil;ok nadir olarak da solunum kaslar\u0131nda paralizi nedeniyle &ouml;l&uuml;m ger&ccedil;ekle\u015fiyor. <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Tedavi i&ccedil;in hastan\u0131n yatakta istirahati sa\u011flan\u0131yor ve tutulan uzvun tamamen rahatlamas\u0131 sa\u011flan\u0131yor. \u015eayet ki\u015fi nefes almakta zorlan\u0131yorsa bir solunum cihaz\u0131 veya eskilerin &lsquo;demir ci\u011feri&rsquo; kullan\u0131l\u0131yor. Gerekirse fizik tedavi uygulan\u0131yor.<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hastal\u0131k risklerinin dan\u0131\u015fana korkutma amac\u0131yla abart\u0131l\u0131 veya yanl\u0131\u015f \u015fekilde aktar\u0131lamayaca\u011f\u0131n\u0131, hekimlerin objektif olarak kar\u015f\u0131s\u0131ndaki bireyin(!) &ccedil;\u0131kar\u0131n\u0131 d&uuml;\u015f&uuml;nerek bu bilgileri objektif olarak aktarmas\u0131 gerekti\u011fini hat\u0131rlatmak istiyorum.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Ve son olarak da hemen bug&uuml;nlerde \u0130stanbul&rsquo;da gizli kapakl\u0131 ba\u015flat\u0131lan polio a\u015f\u0131lamas\u0131yla ilgili (en az\u0131ndan benim) akl\u0131ma tak\u0131lan soru ve sorunlar\u0131 ifade etti\u011fim yorumlar\u0131m\u0131 aktar\u0131yorum:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&ldquo;Sessiz sedas\u0131z (reklams\u0131z) bu defa da zavall\u0131 Suriyeli s\u0131\u011f\u0131nmac\u0131lar ve yabanc\u0131 uyruklular(?) hedef al\u0131n\u0131yordu. Evet, ya\u015fam ko\u015fullar\u0131 &ouml;nemli hastal\u0131k bula\u015f\u0131nda, ancak burada birka&ccedil; a&ccedil;\u0131klanmaya muhta&ccedil; nokta bulunuyordu:<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Polio salg\u0131nlar\u0131n\u0131n genellikle yaz mevsiminin sonunda ortaya &ccedil;\u0131kt\u0131\u011f\u0131n\u0131 biliyoruz. Peki, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ne oldu da yaz\u0131n ba\u015f\u0131nda kampanya ihtiyac\u0131 hissetti? Reklam yapm\u0131yoruz, duyurmuyoruz demelerinin sebebi (elbette siyasi kayg\u0131lar\u0131n yan\u0131nda) insanlar acaba tutar da &ldquo;e hani nerde \u0130stanbul&rsquo;da (veyahut da T&uuml;rkiye&rsquo;nin ba\u015fka herhangi bir ilinde) teyitli polio vakalar\u0131?&rdquo; diye sorar diye mi? D&uuml;nyan\u0131n neresinde g&ouml;r&uuml;lm&uuml;\u015f b&ouml;ylesi sorumsuzluk &ouml;rne\u011fi? E hadi Suriye&rsquo;de (hepsi topu topu 12 vaka) g&ouml;r&uuml;lm&uuml;\u015f, biz kimselere a&ccedil;\u0131klama yapmadan, ortaya veri filan koymadan kafam\u0131za g&ouml;re hedef kitle belirleyelim, anaokullar\u0131nda kre\u015flerde yakalad\u0131\u011f\u0131m\u0131z &ccedil;ocu\u011fu (umuyorum anne-baban\u0131n izni dahilinde!) a\u015f\u0131layal\u0131m tarz\u0131 sorumsuz bir giri\u015fim?<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">2-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Metinde (umuyorum masumane bir ihmalle) T&uuml;rkiye&rsquo;de &ccedil;ocuklar\u0131n takvim gere\u011fi 6. ve 18. aylarda polio a\u015f\u0131s\u0131 oldu\u011fu belirtilmi\u015f.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">a) <\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bu aylarda yap\u0131lan OPA (oral polio a\u015f\u0131s\u0131) ad\u0131ndaki damla \u015feklindeki a\u015f\u0131d\u0131r. Oysa &ccedil;ocuklar bu a\u015f\u0131lar\u0131n yan\u0131 s\u0131ra 2, 4, 6 ve 18. aylarda 5&rsquo;li karma a\u015f\u0131lar\u0131n i&ccedil;inde IPA, yani i\u011fne \u015feklindeki polio a\u015f\u0131s\u0131n\u0131 da oluyor. Mevcut veriler, &ouml;ld&uuml;r&uuml;lm&uuml;\u015f polio vir&uuml;s&uuml; ihtiva eden IPA a\u015f\u0131s\u0131n\u0131n, zay\u0131flat\u0131lm\u0131\u015f canl\u0131 vir&uuml;s a\u015f\u0131s\u0131 olan OPA&rsquo;ya g&ouml;re &ccedil;ok daha etkili oldu\u011funu da g&ouml;sterirken, bizim &ccedil;ocuklar 2 ya\u015f\u0131n alt\u0131nda 4 doz IPA ve 2 doz OPA ile rekor seviyede 6 doz a\u015f\u0131lar\u0131n\u0131 olmuyorlar m\u0131?<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">b)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Haberde polio&rsquo;nun en s\u0131k g&ouml;r&uuml;ld&uuml;\u011f&uuml; ya\u015f\u0131n 5 ya\u015f oldu\u011fu belirtilmi\u015f. L&uuml;tfen Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 a&ccedil;\u0131klas\u0131n, do\u011fumdan 1.5 ya\u015fa kadar 6 doz a\u015f\u0131yla bu &ccedil;ocuklar\u0131n 5 y\u0131l dahi korunmad\u0131\u011f\u0131n\u0131 d&uuml;\u015f&uuml;n&uuml;yorlarsa acaba a\u015f\u0131lar\u0131n etkinli\u011fini ve tabii buradan hareketle bunca dozun gereklili\u011fini sorgulamam\u0131z gerekmiyor mu? Yoksa 6 dozla sa\u011flayamad\u0131klar\u0131 ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n, mucizev&icirc; bir \u015fekilde bir 7. dozla kesin sa\u011flanabilece\u011fini mi s&ouml;ylemek istiyorlard\u0131?<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">3-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Metinde polio&rsquo;ya dair sa\u011f olsunlar hastal\u0131\u011f\u0131 kapan &ccedil;ocuklar\u0131n %95&rsquo;inin belirti bile g&ouml;stermeden hastal\u0131\u011f\u0131 ge&ccedil;irip atlatt\u0131\u011f\u0131na yer vermi\u015fler. Ancak s&ouml;ylenenler yan\u0131nda s&ouml;ylenmeyenler, yar\u0131m b\u0131rak\u0131lan ger&ccedil;eklikler her zaman daha &ouml;nemli bu t&uuml;r oldubittilerde sakl\u0131 bulunuyordu. Bu metinde art\u0131k d&uuml;nya alemin bildi\u011fi, OPA a\u015f\u0131s\u0131n\u0131n <strong>bizzat polio&rsquo;ya yol a&ccedil;abilece\u011fi<\/strong>, a\u015f\u0131y\u0131 olan &ccedil;ocuklar\u0131n d\u0131\u015fk\u0131s\u0131 yoluyla da etrafa vir&uuml;s yayabilece\u011fi ve sa\u011fl\u0131k durumu yerinde olmayanlar\u0131 ciddi \u015fekilde fel&ccedil; riskine soktu\u011fu bilgisi neden yoktu?<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bunun literat&uuml;rde bilinen ismi <strong><em>&ldquo;contact immunity&rdquo;<\/em><\/strong>, yani temas yoluyla pasif ba\u011f\u0131\u015f\u0131klamad\u0131r. Amerikan halk\u0131 devletin kendilerini bu yolla, bir ta\u015fla birka&ccedil; ku\u015f vurma azmiyle, ancak elbette bilgi ve r\u0131zalar\u0131 d\u0131\u015f\u0131nda y\u0131llarca a\u015f\u0131lad\u0131\u011f\u0131n\u0131, sonunda insanlar &ccedil;ocuklar\u0131n\u0131n altlar\u0131n\u0131 de\u011fi\u015ftirirken fel&ccedil; ge&ccedil;irmeye ba\u015flad\u0131\u011f\u0131nda anlam\u0131\u015flard\u0131. Amerikan devleti CDC &uuml;zerinden yapt\u0131\u011f\u0131 a&ccedil;\u0131klamayla &uuml;lkede son 30 y\u0131lda tek bir do\u011fal polio vir&uuml;s&uuml; enfeksiyonu olmad\u0131\u011f\u0131n\u0131, kayda ge&ccedil;en t&uuml;m polio (ve m&uuml;teakip fel&ccedil;) vakalar\u0131n\u0131n a\u015f\u0131 vir&uuml;s&uuml;nden kaynakland\u0131\u011f\u0131n\u0131 a&ccedil;\u0131klam\u0131\u015f ve OPA kullan\u0131mdan kald\u0131r\u0131lm\u0131\u015ft\u0131. Amerika&rsquo;n\u0131n kullanmad\u0131\u011f\u0131 bu riskli a\u015f\u0131y\u0131 Pakistan, Hindistan ve \u015fimdi T&uuml;rkiye a\u011fza \u015fekerli su damlat\u0131r gibi &ccedil;ocuklara doz doz ni&ccedil;in ve nas\u0131l da\u011f\u0131tmaktayd\u0131? Payla\u015f\u0131mlar\u0131 takip edenler, bu art\u0131k hesab\u0131 bile tutulmayan OPA dozlar\u0131n\u0131n Pakistan ve Hindistan&rsquo;da ka&ccedil; &ccedil;ocu\u011fu fel&ccedil; etti\u011fini hat\u0131rlayacakt\u0131r. \u015eimdi, \u015fayet bu kampanyalardan sonra hakikaten polio&rsquo;ya yakalanm\u0131\u015f ve hatta fel&ccedil; ge&ccedil;irmi\u015f &ccedil;ocuklar\u0131n haberleri gelmeye ba\u015flarsa, devletin &ccedil;\u0131k\u0131p <strong><em>&ldquo;evet, bunlar bizim yapt\u0131\u011f\u0131m\u0131z a\u015f\u0131lardan olmu\u015ftur&rdquo; <\/em><\/strong>diyece\u011fini sananlar da yan\u0131lmaktad\u0131r?<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Asemptomatik Bula\u015f ve Bordetella Pertussis (Bo\u011fmaca) Bakterisinin Yeniden Ortaya &Ccedil;\u0131k\u0131\u015f\u0131<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Giri\u015f: <\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">(A\u011f\u0131rl\u0131kl\u0131 olarak &lsquo;Bordetella pertussis&rsquo; bakterisi ile enfeksiyon sonucu olu\u015fmu\u015f) bo\u011fmaca vakalar\u0131nda son y\u0131llarda g&ouml;zlenen art\u0131\u015f, alt\u0131nda yatan mekanizmay\u0131 anlamaya &ccedil;al\u0131\u015fan sa\u011fl\u0131k uzmanlar\u0131 ve bilim adamlar\u0131n\u0131 zor durumda b\u0131rakmaktad\u0131r. Bo\u011fmacan\u0131n yeniden ortaya &ccedil;\u0131k\u0131\u015f\u0131n\u0131 a&ccedil;\u0131klamak i&ccedil;in 3 ana hipotez &ouml;ne s&uuml;r&uuml;lm&uuml;\u015ft&uuml;r:<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131 ya da do\u011fal yolla elde edilmi\u015f koruyucu ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n etkisinin zaman i&ccedil;inde zay\u0131flamas\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">2-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> B. Pertussis bakterisinin yarat\u0131lmaya &ccedil;al\u0131\u015f\u0131lan koruyucu ba\u011f\u0131\u015f\u0131kl\u0131ktan s\u0131yr\u0131labilmek i&ccedil;in zaman i&ccedil;inde evrim ge&ccedil;irmi\u015f olmas\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">3-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131 kapsay\u0131c\u0131l\u0131\u011f\u0131n\u0131n yetersiz kalmas\u0131.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Son d&ouml;nemde yap\u0131lan ara\u015ft\u0131rmalar 4. bir mekanizmay\u0131 daha ortaya &ccedil;\u0131karm\u0131\u015ft\u0131r: <strong><em>kullan\u0131mdaki &lsquo;asel&uuml;ler&rsquo; B. Pertussis a\u015f\u0131lar\u0131n\u0131 olmu\u015f bireylerden &ccedil;evreye asemptomatik bula\u015fma.<\/em><\/strong><\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Metodlar:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Amerika Birle\u015fik Devletleri (ABD) ve Birle\u015fik Krall\u0131k&rsquo;ta (BK) g&ouml;r&uuml;len vakalar i&ccedil;in damlac\u0131k analizi, Amerika&rsquo;dan izole edilmi\u015f 36 klinik B. Pertussis vakas\u0131 i&ccedil;in de filodinamik analiz tekni\u011fi kullan\u0131larak, B. Pertussis bakterisinin asemptomatik (belirti vermeden) bula\u015ft\u0131\u011f\u0131n\u0131 destekleyen kan\u0131tlar elde edilmi\u015ftir. Bunun akabinde bu bulgunun klinik, epidemiyolojik ve toplum sa\u011fl\u0131\u011f\u0131 a&ccedil;\u0131s\u0131ndan do\u011furabilece\u011fi sonu&ccedil;lar matematik modellemeyle incelenmi\u015ftir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Ara\u015ft\u0131rmadan \u015fu sonu&ccedil;lar elde edilmi\u015ftir:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Amerika ve \u0130ngiltere&rsquo;de g&ouml;zlenen ya\u015fa &ouml;zel atak oranlar\u0131ndaki de\u011fi\u015fimlerin zamanlamas\u0131, asemptomatik bula\u015fla tutarl\u0131l\u0131k g&ouml;stermektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">2-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Amerika&rsquo;da g&ouml;r&uuml;len vaka serisini incelemede kullan\u0131lan filodinamik analiz, bakteri pop&uuml;lasyonunun genelinde, g&ouml;zlenen enfeksiyon say\u0131s\u0131n\u0131n bak\u0131larak yap\u0131lacak tahmini orandan daha y&uuml;ksek oranda bir genetik &ccedil;e\u015fitlili\u011fe i\u015faret etmektedir, bu da asemptomatik bula\u015f ile uyu\u015fan bir neticedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">3-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Asemptomatik enfeksiyonlar, a\u015f\u0131n\u0131n B. Pertussis g&ouml;r&uuml;lmeyen haftalardan yola &ccedil;\u0131k\u0131larak yap\u0131lan etkinlik de\u011ferlendirmelerinde sonu&ccedil;lar\u0131n yanl\u0131 olmas\u0131na neden olabilir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">4-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> B. Pertussis insidans\u0131nda g&ouml;zlemlenen art\u0131\u015f, asemptomatik bula\u015fla a&ccedil;\u0131klanabilir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">5-<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Hen&uuml;z a\u015f\u0131lanamayacak kadar k&uuml;&ccedil;&uuml;k bebekleri, &ldquo;kozalama&rdquo; denilen ve bebe\u011fe yak\u0131n temasta olan bireyleri a\u015f\u0131lamak suretiyle korumaya &ccedil;al\u0131\u015fma y&ouml;ntemi fayda vermeyebilir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Yorumlar: Bahsi ge&ccedil;en di\u011fer mekanizmalar\u0131n da rol&uuml; yads\u0131nmamakla birlikte, asemptomatik bula\u015f, B. Pertussis&rsquo;in (bo\u011fmacan\u0131n) Amerika ve \u0130ngiltere&rsquo;de yeniden ba\u015f g&ouml;stermesiyle ilgili g&ouml;zlemleri en iyi a&ccedil;\u0131klayan mekanizma olarak &ouml;ne &ccedil;\u0131kmaktad\u0131r. Elde edilen bu <\/span><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">sonu&ccedil;lar\u0131n<\/span><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> y&uuml;r&uuml;rl&uuml;kteki B. Pertussis (bo\u011fmaca) a\u015f\u0131 politikalar\u0131na &ouml;nemli implikasyonlar\u0131 olmas\u0131n\u0131n yan\u0131 s\u0131ra, s&uuml;r&uuml; ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 (toplumsal ba\u011f\u0131\u015f\u0131kl\u0131k) olu\u015fturma ve B. Pertussis&rsquo;in (bo\u011fmacan\u0131n) eliminasyonu (ortadan kald\u0131r\u0131lmas\u0131) senaryosunu da g&uuml;&ccedil;le\u015ftirmektedir.[7]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Bir profes&ouml;r&uuml;n feryad\u0131: <em>k\u0131zam\u0131k-k\u0131zam\u0131k&ccedil;\u0131k-kabakulak a\u015f\u0131lamas\u0131 derhal ask\u0131ya al\u0131nmal\u0131d\u0131r!<\/em><\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Amerika&rsquo;da ba\u011f\u0131ms\u0131z medyada, g&uuml;nlerdir me\u015fhur CDC (Center for Disease Control and Prevention=Hastal\u0131klar\u0131 Kontrol ve &Ouml;nleme Merkezi) taraf\u0131ndan &ccedil;ocukluk &ccedil;a\u011f\u0131nda mecburi olarak uygulanan MMR (KKK=K\u0131zam\u0131k-K\u0131zam\u0131k&ccedil;\u0131k-Kabakulak) a\u015f\u0131s\u0131n\u0131n, &ccedil;ocuklarda otizm g&ouml;r&uuml;lme s\u0131kl\u0131\u011f\u0131n\u0131 kat kat artt\u0131rd\u0131\u011f\u0131 yaz\u0131l\u0131yordu.[8]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-family: Arial, sans-serif; font-size: 12pt; text-indent: 1cm;\">Ba\u011f\u0131ms\u0131z medyada diyorum! &Ccedil;&uuml;nk&uuml; ge&ccedil;en y\u0131l Taksim&rsquo;den g&uuml;nlerce canl\u0131 yay\u0131n yap\u0131p da, Ferguson&rsquo;daki Gezi benzeri olaylar\u0131 g&ouml;rmezden gelen me\u015fhur CNN ve di\u011ferleri bahsetti\u011fim haberi de g&ouml;rmezden geliyordu.[9]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-family: Arial, sans-serif; font-size: 12pt; text-indent: 1cm;\">\u0130lgin&ccedil; tevafuk(!); sa\u011fl\u0131k ile ilgili haberlerin c\u0131lk\u0131n\u0131 &ccedil;\u0131karan necip T&uuml;rk matbuat\u0131nda da bu konu ile ilgili bir sat\u0131r yer alm\u0131yordu.[10]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-family: Arial, sans-serif; font-size: 12pt; text-indent: 1cm;\">Ancak, ma\u011fdurlar konudan elbette haberdar bulunuyordu. A\u015f\u0131lar\u0131n Snowden&rsquo;i diyebilece\u011fimiz CDC&rsquo;nin k\u0131demli bilim adam\u0131 Dr. William Thompson taraf\u0131ndan MMR a\u015f\u0131s\u0131n\u0131n &ccedil;ocuklarda otizm geli\u015fmesi riskini artt\u0131rd\u0131\u011f\u0131na dair verilerin gizlendi\u011fi if\u015fa ediliyordu. H&acirc;lbuki 2004 y\u0131l\u0131nda Pediatrics&rsquo;te yay\u0131nlad\u0131klar\u0131 &ccedil;al\u0131\u015fma a\u015f\u0131lar\u0131n g&uuml;ya g&uuml;venli oldu\u011funa dair en &ouml;nemli referans olarak g&ouml;steriliyordu.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Hekim arkada\u015flar\u0131m\u0131z\u0131n insan sa\u011fl\u0131\u011f\u0131 i&ccedil;in &ccedil;al\u0131\u015ft\u0131\u011f\u0131ndan maalesef hi&ccedil; \u015f&uuml;phe etmedikleri CDC&rsquo;nin, h&acirc;l&acirc; ilgili dok&uuml;manlar\u0131 Amerikan Kongresi&rsquo;ne teslim etmemesi ise dikkat &ccedil;ekiyordu.[11]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Hemen ard\u0131ndan, CDC&rsquo;nin konuyla ilgili verilerini yeniden de\u011ferlendiren Dr. Hooker&rsquo;in &ccedil;al\u0131\u015fmas\u0131 da MMR a\u015f\u0131s\u0131n\u0131n otizm geli\u015fme riskini artt\u0131rd\u0131\u011f\u0131n\u0131 g&ouml;steriyordu.[12]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-family: Arial, sans-serif; font-size: 12pt; text-indent: 1cm;\">Beyninizdeki gri h&uuml;creler aras\u0131 ba\u011flant\u0131lar\u0131n iyice a&ccedil;\u0131lmas\u0131 i&ccedil;in bir dipnot daha vermek istiyorum; CDC&rsquo;nin o d&ouml;nemdeki a\u015f\u0131 b&ouml;l&uuml;m&uuml; patronu Dr. Julie Gerberding \u015fu anda en b&uuml;y&uuml;k a\u015f\u0131 &uuml;reticisi olan Merck&rsquo;te &ccedil;al\u0131\u015f\u0131yordu.[13]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">MMR a\u015f\u0131s\u0131ndaki k\u0131zam\u0131k vir&uuml;s&uuml;n&uuml;n yol a&ccedil;abilece\u011fi risklere ve &uuml;lkemizde milli a\u015f\u0131 &uuml;retilmesi i&ccedil;in neler yap\u0131lmas\u0131 gerekti\u011fine daha &ouml;nce elimden geldi\u011fince dikkat &ccedil;ekmi\u015ftim.[14]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Kanaatimce, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 derhal MMR a\u015f\u0131s\u0131 uygulamas\u0131n\u0131 ask\u0131ya almal\u0131, &uuml;yelerinin &uuml;&ccedil;te biri ticari firmalar\u0131n temsilcisi olan[15]&nbsp;&lsquo;A\u015f\u0131 Bilim Kurulu&rsquo;nu g&ouml;zden ge&ccedil;irmeli, her biri bir imm&uuml;nolojik deney olan 46 dozluk &ccedil;ocukluk &ccedil;a\u011f\u0131 a\u015f\u0131 takvimini mecburi olmaktan &ccedil;\u0131karmal\u0131, \u0130ngiltere&rsquo;deki gibi tavsiye niteli\u011finde uygulamaya ge&ccedil;melidir. MMR a\u015f\u0131s\u0131 ask\u0131ya al\u0131nd\u0131\u011f\u0131 takdirde olu\u015fabilecek yeg&acirc;ne sorun; b&uuml;t&uuml;n anne adaylar\u0131 &ccedil;ocukken a\u015f\u0131land\u0131\u011f\u0131 ve &lsquo;tabii&rsquo; k\u0131zam\u0131k ge&ccedil;irmedi\u011fi i&ccedil;in dola\u015f\u0131mlar\u0131ndaki k\u0131zam\u0131k antikorlar\u0131n\u0131n &ccedil;ok d&uuml;\u015f&uuml;k olmas\u0131 ve bu sebeple, do\u011furduklar\u0131 bebeklerin bir ya\u015f\u0131na kadar k\u0131zam\u0131\u011f\u0131 a\u011f\u0131r ge&ccedil;irme risklerinin olmas\u0131d\u0131r. Bu sorun A vitamini ve gerekirse IVIG uygulanmas\u0131 ile a\u015f\u0131labilir. Bu vesile ile v&uuml;cuda zerk edildikten sonra geri al\u0131nmas\u0131 imk&acirc;ns\u0131z olan, antidotu-panzehiri olmayan biyoaktif materyalin muhtemel zararlar\u0131 konusunda millet ve memleketimizin &acirc;li menfaatleri a&ccedil;\u0131s\u0131ndan herkesi uyan\u0131k olmaya davet ediyorum.[16]<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Bir bilim adam\u0131n\u0131n uyar\u0131lar\u0131: Zika Vir&uuml;s ve Rockefeller T\u0131bb\u0131!<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Ccedil;ocukluk &ccedil;a\u011f\u0131nda uygulanan a\u015f\u0131lar ile ilgili mant\u0131ks\u0131zl\u0131klar\u0131 ara\u015ft\u0131rd\u0131k&ccedil;a, \u0130ngilizce literat&uuml;rde neler oldu\u011funu anlad\u0131k&ccedil;a, millet ve memleketim i&ccedil;in daha &ccedil;ok &ccedil;al\u0131\u015fmam ve daha &ccedil;ok yaz\u0131 yazmam gerekti\u011fi kanaatim g&uuml;&ccedil;lenmektedir. G&uuml;n&uuml;m&uuml;zde uygulanan, &ouml;\u011fretilen t\u0131bb\u0131n delile dayal\u0131 t\u0131p (evidence-based medicine) denilir ki, baz\u0131 akl-\u0131 evveller buna ortodoks t\u0131p diyor (Latincede ortho dikine, do\u011fru; hetero di\u011fer anlam\u0131na geldi\u011fine g&ouml;re) i\u015flerine gelmeyen bilgi ve uygulamalara heterodoks t\u0131p demekle kendilerini hakl\u0131 g&ouml;stermeye &ccedil;al\u0131\u015f\u0131yorlar. Me\u011fer <em>Ortodoks t\u0131bb\u0131n mucidi de Rockefeller ailesi de\u011fil mi imi\u015f?<\/em><\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Ortaya &ccedil;\u0131kan zikavir&uuml;s olay\u0131n\u0131 biraz kurcalay\u0131nca bu u&ccedil;uk(!) hik&acirc;yelerin asl\u0131nda u&ccedil;uk olmad\u0131\u011f\u0131n\u0131, kar\u015f\u0131m\u0131zda acayip bir sistemin bulundu\u011funu na&ccedil;izane duyurmak isterim. Ahmet Rasim hocan\u0131n konu ile ilgili ve ilgin&ccedil; ba\u011flant\u0131lar\u0131 f&acirc;\u015f eden yaz\u0131s\u0131na b\u0131rakt\u0131\u011f\u0131m yorumda <strong><em>&ldquo;Neden son on y\u0131ld\u0131r K\u0131r\u0131m-Kongo gibi daha &ouml;nce ad\u0131n\u0131 bile duymad\u0131\u011f\u0131m\u0131z garip hastal\u0131klar peydah oluyor ve neden bu hastal\u0131klar\u0131n etkenleri daha &ouml;nce laboratuarlarda &uuml;retiliyor ve &uuml;zerlerinde &ccedil;al\u0131\u015f\u0131l\u0131yor durumda?&rdquo;<\/em><\/strong> sualini tevcih etmi\u015ftim. Nitekim bug&uuml;n yay\u0131nlanan &ldquo;Zikavir&uuml;s&uuml; kimin?&rdquo; ba\u015fl\u0131kl\u0131 yaz\u0131da a&ccedil;\u0131k&ccedil;a zikavir&uuml;s patentinin (bu da ne demekse ve de nas\u0131l k&acirc;bil olabiliyorsa!?) ila&ccedil; imparatoru da denilen (k&uuml;resel-Siyonist s&ouml;m&uuml;r&uuml; sermayesi baronlar\u0131ndan) Rockefeller Foundation&rsquo;a ait oldu\u011fu kaynak g&ouml;sterilerek belirtilmi\u015ftir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Zikavir&uuml;s neden m&uuml;himdir?<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Ccedil;&uuml;nk&uuml; (Amerikan Enfeksiyon Hastal\u0131klar\u0131 M&uuml;d&uuml;rl&uuml;\u011f&uuml;) CDC&rsquo;nin; (Ahmet Rasim hoca gibi, ben de bu CDC&rsquo;ye komedi merkezi demek istiyorum) haftal\u0131k &ouml;l&uuml;m ve hastal\u0131k raporunda (MMWR), bu vir&uuml;s&uuml;n hamile kad\u0131nlara bula\u015ft\u0131\u011f\u0131nda fet&uuml;ste mikrosefaliye (ba\u015f\u0131n ve dolay\u0131s\u0131 ile beynin k&uuml;&ccedil;&uuml;kl&uuml;\u011f&uuml; ile kendini g&ouml;steren &ccedil;ok a\u011f\u0131r bir do\u011fum anomalisi) yol a&ccedil;t\u0131\u011f\u0131 iddia ediliyor. Fakat bu rapor &ccedil;ok garip do\u011frusu; Brezilya&rsquo;da 2015 y\u0131l\u0131nda 35 (otuz be\u015f) adet annenin hamileli\u011fi esnas\u0131nda vir&uuml;s&uuml;n tesbit edildi\u011fi yerlerde bulundu\u011fu bilinen mikrosefali vakas\u0131 belirlenmi\u015f, vir&uuml;s&uuml;n varl\u0131\u011f\u0131 ve bebeklerin ger&ccedil;ekten miksrosefalik olup olmad\u0131klar\u0131 (erken do\u011fum sebebi ile) belirtilmiyor. Hani 4000&rsquo;den fazla zikavir&uuml;sl&uuml; ve mikrosefalili bebek vard\u0131? Zika ve mikrosefali konusunda Dr. Jason Tetro&rsquo;nun bu durumun tesad&uuml;fi olabilece\u011fi yorumu daha makul g&ouml;r&uuml;n&uuml;yor. Me\u015fhur t\u0131p k&uuml;t&uuml;phanesi pubmede &ldquo;zika&rdquo; yazd\u0131\u011f\u0131n\u0131zda &ccedil;ok az say\u0131da yaz\u0131 oldu\u011funu, bunlar\u0131n sadece 10 kadar\u0131n\u0131n bu vir&uuml;s hakk\u0131nda derleme makalesi oldu\u011funu, di\u015fe dokunur tek yaz\u0131n\u0131n ise Edward B. Hayes taraf\u0131ndan kaleme al\u0131nm\u0131\u015f olan &ldquo;Afrika d\u0131\u015f\u0131nda Zikavir&uuml;s&rdquo; makalesi oldu\u011funu g&ouml;r&uuml;yoruz. Makaleyi okudu\u011fumuzda, yazar\u0131n bu konuda muhtemelen en &ouml;nemli ki\u015fi oldu\u011funu, vir&uuml;s&uuml;n ise 1942&rsquo;de maymunlarda tesbit edildi\u011fini, sar\u0131humma ve deng gibi bilhassa Amerika k\u0131tas\u0131nda &ouml;nemli hastal\u0131klar yapabilen vir&uuml;slerden oldu\u011funu, t\u0131pk\u0131 bu hastal\u0131klarda oldu\u011fu gibi sivrisineklerle ta\u015f\u0131nd\u0131\u011f\u0131n\u0131 (tahtakurusu &ouml;rne\u011fimi hat\u0131rlad\u0131n\u0131z m\u0131, enfeksiyoncu biraderler?), insanlarda ilk defa 1970&rsquo;lerde Nijerya&rsquo;da tesbit edildi\u011fini, hafif bir ate\u015fli hastal\u0131k yapt\u0131\u011f\u0131n\u0131 belirtiyor. Gebelikle ilgili bir bilgi verilmemi\u015f. Yakla\u015f\u0131k yetmi\u015f y\u0131ld\u0131r bilinen bir vir&uuml;s (hastal\u0131k de\u011fil!) ve birden salg\u0131n yap\u0131yor, mikrosefali yapt\u0131\u011f\u0131 iddia ediliyor, Allah Allah&hellip; Nedense akl\u0131ma a\u015f\u0131lar\u0131n maymun dokular\u0131nda &uuml;retildi\u011fi, bu a\u015f\u0131lar\u0131n da tam da o d&ouml;nemlerde gariban Afrikal\u0131larda denendi\u011fi, gelmi\u015f ge&ccedil;mi\u015f en b&uuml;y&uuml;k a\u015f\u0131 geli\u015ftirici Dr. Maurice Hilleman&rsquo;\u0131n, a\u015f\u0131lardaki kanser m&uuml;sebbibi SV40 vir&uuml;s&uuml; kontaminasyonu geliverdi. &Ccedil;ocuk imm&uuml;nologu ne anlar bunlardan can\u0131\u0131\u0131m!<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bu yaz\u0131y\u0131 yazmak i&ccedil;in Dr. Hayes&rsquo;a mail g&ouml;nderdim, fakat teslim edilemedi mesaj\u0131 ald\u0131m, Google amcaya sordu\u011fumda maatteess&uuml;f ac\u0131 haberi ald\u0131m, adamca\u011f\u0131z 9 May\u0131s 2013&rsquo;te daha 57 ya\u015f\u0131nda kalp krizinden vefat etmemi\u015f miydi? Yine maatteess&uuml;f ba\u015fka bir \u015fey bulmak da m&uuml;mk&uuml;n de\u011fildi. Gelelim neticeye; Ben size mikrobiyolog ve enfeksiyonculara g&ouml;z&uuml;m&uuml;z gibi bakmam\u0131z gerekti\u011fini, a\u015f\u0131lar\u0131n ne kadar &ouml;nemli oldu\u011funu s&ouml;ylememi\u015f miydim!?<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">A\u015f\u0131lar tart\u0131\u015f\u0131lmal\u0131d\u0131r!&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">T&uuml;rkiye&rsquo;de ailelerin bebek ve &ccedil;ocuk a\u015f\u0131lar\u0131na kar\u015f\u0131 giderek artan ku\u015fkucu yakla\u015f\u0131m\u0131 ile birlikte a\u015f\u0131s\u0131z &ccedil;ocuk say\u0131s\u0131ndaki t\u0131rman\u0131\u015f, ba\u015fta sa\u011fl\u0131k uzmanlar\u0131 olmak &uuml;zere pozitif d&uuml;\u015f&uuml;nceyi temsil eden ayd\u0131nlar\u0131n &ccedil;o\u011funu, a\u015f\u0131 savunmas\u0131 cephesinde birle\u015ftiriyordu. Oysa ku\u015fkusuz iyi niyetli bu ki\u015filerin, &lsquo;a\u015f\u0131 yararl\u0131d\u0131r&rsquo; kesinli\u011finin arkas\u0131nda cephele\u015fmesi; a\u015f\u0131 kar\u015f\u0131tlar\u0131n\u0131n &lsquo;zararl\u0131d\u0131r&rsquo; fikrini sa\u011flam gerek&ccedil;elere dayand\u0131rmadan benimsemesi kadar yanl\u0131\u015f bulunuyordu. &Ccedil;&uuml;nk&uuml; herhangi bir konuda ku\u015fkuyu elinin tersiyle itip sorgulamay\u0131 reddetmek rasyonel de\u011fildir, dolay\u0131s\u0131yla bilimsel ger&ccedil;ekli\u011fi de olamazd\u0131. Bilimsel mant\u0131k her \u015feyi, yeni verilerin \u0131\u015f\u0131\u011f\u0131nda her zaman yeniden sorgulamay\u0131 gerektirirdi ve zaten b&ouml;yle ilerlerdi.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">T&uuml;rkiye&rsquo;deki a\u015f\u0131 kar\u015f\u0131tl\u0131\u011f\u0131, d&uuml;nyan\u0131n her yan\u0131nda art\u0131yordu! <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Fransa&rsquo;da, h&uuml;k&uuml;metin D&uuml;nya Sa\u011fl\u0131k &Ouml;rg&uuml;t&uuml; ve AB&rsquo;nin kararlar\u0131na uyarak &ccedil;ocuklara zorunlu yap\u0131lan 3 a\u015f\u0131y\u0131 2018 ba\u015f\u0131ndan beri 11&rsquo;e &ccedil;\u0131karmas\u0131, halen grevlerden daha derin ve kal\u0131c\u0131 bir muhalif hareket yaratt\u0131, giderek de yay\u0131l\u0131yor. Le Point dergisinin yay\u0131mlad\u0131\u011f\u0131 bir kamuoyu yoklamas\u0131, Frans\u0131z halk\u0131n\u0131n y&uuml;zde 41&rsquo;inin a\u015f\u0131 olgusuna t&uuml;mden kar\u015f\u0131 oldu\u011funu g&ouml;steriyor. Ama a\u015f\u0131ya kar\u015f\u0131 olmayanlar bile, &ccedil;ocu\u011funa 11 zorunlu a\u015f\u0131 yapt\u0131rmaya raz\u0131 de\u011fil. Her g&uuml;n bir olay var ve h&uuml;k&uuml;metin ald\u0131\u011f\u0131 karar, hen&uuml;z uygulamaya konulamad\u0131; bu gidi\u015fle de hi&ccedil; kolay olmayacak gibi g&ouml;r&uuml;n&uuml;yor.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Direni\u015f&ccedil;iler &ouml;rg&uuml;tleniyor, h&uuml;k&uuml;met AB&rsquo;deki ila&ccedil; lobilerine teslim olmakla su&ccedil;lan\u0131yor, parlamenterlere mektuplar yaz\u0131l\u0131yor, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131&rsquo;na davalar a&ccedil;\u0131l\u0131yor. Zorunlu a\u015f\u0131 say\u0131s\u0131n\u0131n artt\u0131r\u0131lmas\u0131na itiraz edenlerin ba\u015f\u0131nda, genel sa\u011fl\u0131k hekimleri var. Uzman hekimler ise ikiye ayr\u0131lm\u0131\u015f durumda, kamusal alanda &ccedil;ok sert tart\u0131\u015fmalar i&ccedil;ine girdiler. Ancak her ge&ccedil;en g&uuml;n zorunlu a\u015f\u0131lar\u0131 savunanlar\u0131n i\u015fi zorla\u015f\u0131yor, &ccedil;&uuml;nk&uuml; a\u015f\u0131r\u0131 say\u0131da a\u015f\u0131n\u0131n zarar\u0131n\u0131 vurgulayan cephe, bug&uuml;ne kadar ad\u0131 ge&ccedil;ti\u011finde aya\u011fa kalk\u0131p selam durduklar\u0131, \u015fimdiyse yerden yere vurduklar\u0131 t\u0131p otoritelerinin kat\u0131l\u0131m\u0131yla geni\u015fliyor. Bunlardan biri, imm&uuml;n sistem vir&uuml;s&uuml; ke\u015ffiyle Nobel &ouml;d&uuml;l&uuml; alan virolog Prof. Dr. Luc Montaigner. Bir di\u011feri, kanserle m&uuml;cadelede ulusal madalyal\u0131 Prof. Dr. Henri Joyeux. Bu ikili, &lsquo;Akl\u0131selime &ccedil;a\u011fr\u0131&rsquo; ba\u015fl\u0131\u011f\u0131 alt\u0131nda bir bildiri yay\u0131mlad\u0131. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><em><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">&ldquo;A\u015f\u0131ya kar\u015f\u0131 de\u011filiz. 2 ya\u015f\u0131ndan k&uuml;&ccedil;&uuml;k &ccedil;ocuklar\u0131n &ccedil;ok say\u0131da ve sistematik olarak a\u015f\u0131lanmas\u0131na kar\u015f\u0131y\u0131z&rdquo; <\/span><\/em><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">a&ccedil;\u0131klamas\u0131yla ba\u015flayan metinde, Hepatit B a\u015f\u0131s\u0131n\u0131n sadece ebeveynlerden birinin vir&uuml;s ta\u015f\u0131y\u0131c\u0131 olmas\u0131 \u015fart\u0131yla ve ergenlik sonras\u0131 ya\u015fad\u0131\u011f\u0131 ya da &ccedil;al\u0131\u015ft\u0131\u011f\u0131 ortam risk ta\u015f\u0131yorsa, 15 ya\u015f\u0131ndan sonra yap\u0131lmas\u0131 gerekti\u011fi vurgulan\u0131yordu. Menengogok ile k\u0131zam\u0131k a\u015f\u0131s\u0131 gibi baz\u0131 a\u015f\u0131lar\u0131n da ancak salg\u0131n durumunda uygulanmas\u0131 savunuluyordu. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">A\u015f\u0131lardaki n&ouml;rotoksik al&uuml;minyum katk\u0131s\u0131 yerine kalsiyum fosfat kullan\u0131lmas\u0131 &ouml;neriliyordu. <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">\u0130la&ccedil; sanayisini rant i\u015ftah\u0131yla su&ccedil;layan ve baz\u0131lar\u0131n\u0131n yarars\u0131zl\u0131\u011f\u0131 kan\u0131tlanm\u0131\u015f a\u015f\u0131r\u0131 say\u0131da a\u015f\u0131 yapman\u0131n g&ouml;z ard\u0131 edilemeyecek risklerini s\u0131ralayan bu &ccedil;ok ayr\u0131nt\u0131l\u0131 bildiriyi, yar\u0131ya yak\u0131n\u0131 doktor olan, 8 bin ki\u015fi imzalam\u0131\u015f bulunuyordu. Le Parisien gazetesi, Frans\u0131z Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131&rsquo;n\u0131n bir ara\u015ft\u0131rma ekibine gizlice \u0131smarlad\u0131\u011f\u0131 a\u015f\u0131lardaki al&uuml;minyum raporunu ele ge&ccedil;irip yay\u0131ml\u0131yordu. Sonu&ccedil;lar deh\u015fet vericiydi: Evet, al&uuml;minyum b&ouml;brek, karaci\u011fer, dalak ve pankreasta birikerek kana kar\u0131\u015f\u0131yor, beyne gidiyor. Dolay\u0131s\u0131yla &ccedil;ok vahim otoimm&uuml;n ve n&ouml;rolojik hastal\u0131klara yol a&ccedil;abiliyordu. Sizin anlayaca\u011f\u0131n\u0131z, a\u015f\u0131lar tart\u0131\u015fma d\u0131\u015f\u0131 b\u0131rak\u0131lamaz ve a\u015f\u0131r\u0131 a\u015f\u0131lamadan ka&ccedil;\u0131nmak, ilk ihtiyat &ouml;nlemi. Ama as\u0131l yap\u0131lmas\u0131 gereken, al&uuml;minyumsuz a\u015f\u0131 &uuml;retimi oluyordu. Bu ihtiyat\u0131n kar\u015f\u0131l\u0131\u011f\u0131, &lsquo;a\u015f\u0131lar\u0131n sa\u011flad\u0131\u011f\u0131 koruma, ta\u015f\u0131d\u0131klar\u0131 riskten &ccedil;ok daha fazla&rsquo; gerek&ccedil;esi olamazd\u0131. Hayat piyango olabilir, ama hi&ccedil;bir &ccedil;ocu\u011fa risk bileti kesilmemesi gerekiyordu.[17]<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">De\u011ferli bilim adam\u0131m\u0131z ve yak\u0131ndan tan\u0131d\u0131\u011f\u0131m\u0131z Ahmet Rasim K&uuml;&ccedil;&uuml;kusta, ilgili ve yetkili mercileri \u015f&ouml;yle uyarmaktayd\u0131: A<\/span><\/strong><strong style=\"text-indent: 1cm;\"><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">\u015f\u0131 say\u0131s\u0131 artt\u0131k&ccedil;a bebek &ouml;l&uuml;mleri azalmay\u0131p, artmaktad\u0131r!<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bu yaz\u0131m\u0131 bilim yobazlar\u0131na inat <strong><em>&#8220;A\u015f\u0131lar tart\u0131\u015f\u0131lmal\u0131d\u0131r&#8221;<\/em><\/strong> diyen Mine G. K\u0131r\u0131kkanat&#8217;a ithaf ediyorum.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">A\u015f\u0131 say\u0131s\u0131 artt\u0131k&ccedil;a hastal\u0131klar\u0131n ve bunlara ba\u011fl\u0131 komplikasyon ve &ouml;l&uuml;mlerin azalaca\u011f\u0131 d&uuml;\u015f&uuml;n&uuml;lebilir. Ama bunun do\u011fru olmayabilece\u011fini g&ouml;steren, &ldquo;end&uuml;stri ile menfaat m&uuml;nasebeti olmayan ba\u011f\u0131ms\u0131z uzmanlar taraf\u0131ndan&rdquo; ger&ccedil;ekle\u015ftirilen &ouml;nemli bir ara\u015ft\u0131rma vard\u0131r. USA ki\u015fi ba\u015f\u0131na en &ccedil;ok sa\u011fl\u0131k harcamas\u0131n\u0131 yapan ve 1 ya\u015f\u0131ndan k&uuml;&ccedil;&uuml;k bebeklere 26 a\u015f\u0131 yap\u0131lan tek &uuml;lke olmakla beraber, daha az a\u015f\u0131 uygulanan 33 &uuml;lkede &ldquo;bebek &ouml;l&uuml;m oranlar\u0131 (IMR)&rdquo; USA&rsquo;dan daha d&uuml;\u015f&uuml;k bulunmaktad\u0131r. USA&rsquo;da 2 ya\u015f\u0131na kadar 14 etkene ait toplam 26 doz, 6 ya\u015f\u0131na kadar toplam 49 doz, 18 ya\u015f\u0131na kadar ise, 16 etkene ait a\u015f\u0131lardan toplam 69 doz uygulanmaktad\u0131r. IMR; Singapur ve \u0130sve&ccedil;&rsquo;te, USA&rsquo;dakinin yar\u0131s\u0131ndan azd\u0131r. Japonya&rsquo;da 2.80&rsquo;in de alt\u0131ndad\u0131r ve CDC&rsquo;ye g&ouml;re USA&rsquo;da durum daha da k&ouml;t&uuml;le\u015fmeye ba\u015flam\u0131\u015ft\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><em><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">&ldquo;&Ccedil;ok a\u015f\u0131 daha az bebek &ouml;l&uuml;m&uuml; demek&rdquo;<\/span><\/em><\/strong><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\"> yanl\u0131\u015ft\u0131r!<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">2009&rsquo;da; 34 &uuml;lke i&ccedil;inde en d&uuml;\u015f&uuml;k IMR sahip olan be\u015f &uuml;lkede 1 ya\u015f\u0131na kadar sadece 12 doz a\u015f\u0131 yap\u0131lmakta iken, bu oran USA&rsquo;da 26&rsquo;d\u0131r. Enfeksiyonlardan korunmada esas &ouml;nemli olan temiz su, kanalizasyon, hijyen, uygun beslenme ve sa\u011fl\u0131k kurulu\u015flar\u0131na eri\u015fim gibi fakt&ouml;rlerdir. Gambia&rsquo;da bebeklik &ccedil;a\u011f\u0131nda 22 doz a\u015f\u0131 y&uuml;zde 91-97 oran\u0131nda uygulanmas\u0131na kar\u015f\u0131l\u0131k, IMR&rsquo;nin 68.8 ve 22 doz a\u015f\u0131n\u0131n y&uuml;zde 95-98 oran\u0131nda uyguland\u0131\u011f\u0131 Mo\u011folistan&rsquo;da 39.9 olmas\u0131, tek ba\u015f\u0131na a\u015f\u0131laman\u0131n IMR&rsquo;ye etkisinin olmad\u0131\u011f\u0131n\u0131 g&ouml;sterir. Ani bebek &ouml;l&uuml;m&uuml; sendromu (SIDS) ile a\u015f\u0131lar aras\u0131nda herhangi bir korelasyon olmad\u0131\u011f\u0131n\u0131 bildiren ara\u015ft\u0131rmalar da bulunmakla beraber, baz\u0131 bebeklerin SIDS&rsquo;a daha duyarl\u0131 olabilece\u011fi sonucuna varan ara\u015ft\u0131rmalar nedense gizlenmektedir. Bu bilgiler, &ccedil;ocuk sa\u011fl\u0131\u011f\u0131 ve &uuml;lkelerin genel geli\u015fmi\u015fli\u011fini g&ouml;steren en &ouml;nemli &ouml;l&ccedil;&uuml;lerden biri olan bebek &ouml;l&uuml;m oranlar\u0131n\u0131n (IMR), a\u015f\u0131lama ile do\u011frudan bir ili\u015fkisi olmad\u0131\u011f\u0131n\u0131n, hatta a\u015f\u0131 say\u0131s\u0131n\u0131 art\u0131rman\u0131n faydadan ziyade, zarar getirebilece\u011finin a&ccedil;\u0131k ve net bir g&ouml;stergesidir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Daha &ccedil;ok a\u015f\u0131 daha iyi koruma sa\u011flamamaktad\u0131r!<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Daha &ccedil;ok a\u015f\u0131 yap\u0131lmas\u0131n\u0131n daha fazla koruma anlam\u0131na gelmedi\u011fi, her sene grip a\u015f\u0131s\u0131 yapt\u0131ranlar\u0131n, be\u015f senede bir yapt\u0131ranlara g&ouml;re gribe daha &ccedil;ok yakaland\u0131klar\u0131, iki sene arka arkaya grip a\u015f\u0131s\u0131 olanlarda a\u015f\u0131n\u0131n etkinli\u011finin azald\u0131\u011f\u0131 da biliniyordu. Hatta grip a\u015f\u0131lar\u0131n\u0131n bir pandemi &ccedil;\u0131kt\u0131\u011f\u0131nda b\u0131rak\u0131n koruyucu olmas\u0131n\u0131, daha &ldquo;&ouml;l&uuml;mc&uuml;l grip vakalar\u0131na&rdquo; yol a&ccedil;abilece\u011fi (Kanada fenomeni) de hem epidemiyolojik hem laboratuvar ara\u015ft\u0131rmalar\u0131yla g&ouml;steriliyordu. &Uuml;nl&uuml; CIDRAP raporunda, CDC&rsquo;nin 6 ayl\u0131ktan b&uuml;y&uuml;k &ccedil;ocuklara her sene yap\u0131lmas\u0131n\u0131 tavsiye etti\u011fi grip a\u015f\u0131lar\u0131n\u0131n, 2 ya\u015f\u0131ndan k&uuml;&ccedil;&uuml;klerde etkili oldu\u011funu g&ouml;steren yeterli veri olmad\u0131\u011f\u0131 bildiriliyordu. Randomize kontroll&uuml; ara\u015ft\u0131rmalar grip a\u015f\u0131lar\u0131n\u0131n &ccedil;ocuk ast\u0131ml\u0131larda da i\u015fe yaramad\u0131\u011f\u0131 gibi ast\u0131m krizlerini art\u0131rabilece\u011fini de g&ouml;zler &ouml;n&uuml;ne seriyordu.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Ccedil;ocukluk &ccedil;a\u011f\u0131n\u0131n tabii enfeksiyonlar\u0131 bir&ccedil;ok hastal\u0131\u011fa kar\u015f\u0131 do\u011fal koruma olu\u015fturmaktad\u0131r<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Ccedil;ocukluk &ccedil;a\u011f\u0131nda ge&ccedil;irilen enfeksiyonlar\u0131n ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin g&uuml;&ccedil;lenmesinde &ouml;nemli rol&uuml; oldu\u011funu, mikroplarla daha az kar\u015f\u0131la\u015f\u0131lmas\u0131n\u0131n ba\u015fka hastal\u0131klar\u0131n riskini art\u0131rabilece\u011fini g&ouml;steren pek &ccedil;ok ara\u015ft\u0131rma bulunuyor. Hijyen teorisine g&ouml;re &ccedil;ocukluk &ccedil;a\u011f\u0131nda ge&ccedil;irilen enfeksiyonlar ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131 kuvvetlendirerek ast\u0131m, egzama, saman nezlesi gibi alerjik hastal\u0131klara ve akut lenfoblastik l&ouml;semiye kar\u015f\u0131 koruma sa\u011fl\u0131yor. &Ccedil;ocukken k\u0131zam\u0131k ve kabakulak ge&ccedil;iren erkeklerde kalp krizi y&uuml;zde 29, inme ise y&uuml;zde 17 daha az g&ouml;r&uuml;l&uuml;yor. Her iki enfeksiyonu ge&ccedil;iren kad\u0131nlarda ise kalp krizlerine y&uuml;zde 17, inmelere ise y&uuml;zde 16 daha az rastlan\u0131yor. Epidemiyolojik olarak kabakulak ge&ccedil;iren k\u0131z &ccedil;ocuklar\u0131nda yumurtal\u0131k kanserinin daha az g&ouml;r&uuml;ld&uuml;\u011f&uuml; biliniyor. Yeni bir ara\u015ft\u0131rmada bu koruman\u0131n iltihapl\u0131 t&uuml;k&uuml;r&uuml;k bezinde kanserle ili\u015fkili MUC-1 antijenine kar\u015f\u0131 olu\u015fan antikorlarla ilgili oldu\u011fu g&ouml;steriliyor.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Netice olarak: Prof. Dr. Ali\u015fan Y\u0131ld\u0131ran diyor ki: <em>&ldquo;Basit bir &ccedil;ocukluk &ccedil;a\u011f\u0131 hastal\u0131\u011f\u0131 olan su&ccedil;i&ccedil;e\u011fi i&ccedil;in a\u015f\u0131 yapmak anlams\u0131z ve &uuml;stelik tehlikelidir (vaccine virus shedding). Su&ccedil;i&ccedil;e\u011fi insanlarda hastal\u0131k yapan en &ouml;nemli vir&uuml;s ailesi olan herpesvir&uuml;slere kar\u015f\u0131 heterosubtipik imm&uuml;nite (&ccedil;apraz ba\u011f\u0131\u015f\u0131kl\u0131k da diyebiliriz) temin eder, bunun i&ccedil;in ad&ouml;lesan &ccedil;a\u011f\u0131ndan &ouml;nce nat&uuml;rel olarak ge&ccedil;irilmi\u015f olmas\u0131 gerekir. Bu tabii avantaj; ad\u0131 ge&ccedil;en a\u015f\u0131n\u0131n yap\u0131lmas\u0131, yani insan eli ile yok edilmektedir, di\u011fer mahzurlar\u0131 ise cabas\u0131!&rdquo;<\/em><\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Biz a\u015f\u0131ya kar\u015f\u0131 de\u011filiz. Ancak 2 ya\u015f\u0131ndan k&uuml;&ccedil;&uuml;k &ccedil;ocuklar\u0131n &ccedil;ok say\u0131da ve sistematik olarak a\u015f\u0131lanmas\u0131na kar\u015f\u0131y\u0131z!<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">\u0130mm&uuml;n sistem vir&uuml;s&uuml; ke\u015ffiyle Nobel &ouml;d&uuml;l&uuml; alan virolog Prof. Dr. Luc Montaigner ve kanserle m&uuml;cadelede ulusal madalyal\u0131 Prof. Dr. Henri Joyeux&rsquo;un &lsquo;Akl\u0131selime &ccedil;a\u011fr\u0131&rsquo; ba\u015fl\u0131\u011f\u0131 alt\u0131nda yay\u0131nlad\u0131klar\u0131 bildiri \u015fu s&ouml;zlerle ba\u015fl\u0131yor: <strong><em>&ldquo;A\u015f\u0131ya kar\u015f\u0131 de\u011filiz. 2 ya\u015f\u0131ndan k&uuml;&ccedil;&uuml;k &ccedil;ocuklar\u0131n &ccedil;ok say\u0131da ve sistematik olarak a\u015f\u0131lanmas\u0131na kar\u015f\u0131y\u0131z&rdquo;.<\/em><\/strong><\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">\u0130la&ccedil; sanayisini rant i\u015ftah\u0131yla su&ccedil;layan ve baz\u0131lar\u0131n\u0131n yarars\u0131zl\u0131\u011f\u0131 kan\u0131tlanm\u0131\u015f a\u015f\u0131r\u0131 say\u0131da a\u015f\u0131 yapman\u0131n g&ouml;z ard\u0131 edilemeyecek risklerini s\u0131ralayan bu bildiriyi, yar\u0131ya yak\u0131n\u0131 doktor olan, 8 bin ki\u015fi imzalam\u0131\u015f bulunuyor. Bu kanaat, sadece bu ikiliye ait olmay\u0131p ba\u015fka bilim adam\u0131 ve hekimler taraf\u0131ndan genel t\u0131p bilgileri ve bilimsel ara\u015ft\u0131rmalara dayan\u0131larak dile getirilen, bilimsel ve halk sa\u011fl\u0131\u011f\u0131n\u0131 g&ouml;zeten bir g&ouml;r&uuml;\u015ft&uuml;r ve ben de bu g&ouml;r&uuml;\u015f&uuml; destekliyorum. Bu g&ouml;r&uuml;\u015f, &ldquo;A\u015f\u0131lar\u0131n tart\u0131\u015f\u0131lmas\u0131n\u0131 &ouml;nleyerek&rdquo; &ccedil;\u0131karacaklar\u0131 her yeni a\u015f\u0131n\u0131n &ldquo;&ccedil;atlak bir ses &ccedil;\u0131kmadan&rdquo; yayg\u0131n &ldquo;t&uuml;ketimini&rdquo; sa\u011flamak amac\u0131ndaki a\u015f\u0131 end&uuml;strisinin t&uuml;ylerini diken diken ediyor, asab\u0131n\u0131 bozuyor. Bu ifadeden, &ccedil;ocuklara &ldquo;hi&ccedil;bir a\u015f\u0131 yap\u0131lmas\u0131n&rdquo; veya &ldquo;a\u015f\u0131lar zararl\u0131d\u0131r&rdquo; \u015feklinde bir sonu&ccedil; &ccedil;\u0131karan end&uuml;strinin yapt\u0131\u011f\u0131 &ldquo;&ouml;k&uuml;z alt\u0131nda buza\u011f\u0131 aramaktan&rdquo; ba\u015fka bir \u015fey de\u011fildir! Bu s&ouml;zler, &ccedil;ocuklara her ge&ccedil;en sene daha &ccedil;ok a\u015f\u0131 yap\u0131lmas\u0131 ve bunlar\u0131n da bilhassa 2 ya\u015f\u0131ndan &ouml;nce uygulanmas\u0131n\u0131n yarataca\u011f\u0131 risklerden duyulan &ldquo;endi\u015feyi&rdquo; dile getirmektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Bu endi\u015fenin bilimsel temelleri ve gerek&ccedil;eleri de \u015funlard\u0131r:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Bir:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Yeni do\u011fan ve s&uuml;t &ccedil;ocuklar\u0131n\u0131n (2 ya\u015f alt\u0131) ba\u011f\u0131\u015f\u0131kl\u0131k sistem &ouml;zellikleri, a\u015f\u0131lara ve &ccedil;oklu a\u015f\u0131 uygulamalar\u0131na verdikleri cevap ile ilgili ara\u015ft\u0131rma ve bilgiler olduk&ccedil;a s\u0131n\u0131rl\u0131 ve kifayetsizdir. Bu sebeple de bu k&uuml;&ccedil;&uuml;k &ccedil;ocuklara her &ccedil;\u0131kan yeni a\u015f\u0131n\u0131n yap\u0131lmas\u0131n\u0131n emniyeti belli de\u011fildir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">\u0130ki:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131lama konusunda en &ouml;nemli uzmanlardan biri olan Siegrist, mevcut a\u015f\u0131lar\u0131n antikor ba\u011f\u0131ml\u0131 ve k\u0131sa s&uuml;reli koruma sa\u011flayabilece\u011fini, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ve sa\u011fl\u0131k &uuml;zerine uzun d&ouml;nemdeki etkilerinin bilinmedi\u011fini belirtmektedir. A\u015f\u0131 say\u0131s\u0131 artt\u0131k&ccedil;a a\u015f\u0131yla ilgili riskler de art\u0131verecektir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&Uuml;&ccedil;: <\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Sinir sistemi mat&uuml;rasyonunu ancak iki ya\u015f\u0131nda tamamlar (y&uuml;r&uuml;me ve konu\u015fma ancak bundan sonra m&uuml;mk&uuml;n olmaktad\u0131r), geli\u015fimine daha sonra da devam edecektir. Bu bak\u0131mdan a\u015f\u0131lar\u0131n sinir sistemi &uuml;zerindeki muhtemel oto-imm&uuml;n etkileri g&ouml;z ard\u0131 edilmemelidir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">D&ouml;rt:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Bir&ccedil;ok kronik enflamatuar hastal\u0131\u011f\u0131n ortaya &ccedil;\u0131kmas\u0131nda &ccedil;ok &ouml;nemli rol&uuml; oldu\u011fu son senelerde anla\u015f\u0131lan &ldquo;mikrobiyomun&rdquo; (ba\u011f\u0131rsak mikrobiyotas\u0131n\u0131n) erken &ccedil;ocukluk d&ouml;neminde uygulanan a\u015f\u0131lardan nas\u0131l etkilendi\u011fi ve giderek say\u0131lar\u0131 artan a\u015f\u0131lar\u0131n riskleri de hen&uuml;z bilinmemektedir. Bu bilgilerin artmas\u0131yla bug&uuml;nk&uuml; a\u015f\u0131lama uygulamalar\u0131n\u0131n ciddi \u015fekilde de\u011fi\u015fikli\u011fe u\u011framas\u0131 kuvvetle muhtemeldir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Be\u015f:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> &ldquo;A\u015f\u0131 say\u0131s\u0131n\u0131 art\u0131rman\u0131n potansiyel risklerinin&rdquo; &ccedil;ok iyi de\u011ferlendirilmesi gerekti\u011fini savunan &Ccedil;ocuk \u0130mm&uuml;noloji-Alerji Uzman\u0131 Prof. Dr. Ali\u015fan Y\u0131ld\u0131ran da diyor ki: <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><em><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&ldquo;&Ccedil;ocukluk &ccedil;a\u011f\u0131nda bilhassa hayat\u0131n ilk iki y\u0131l\u0131ndaki bir bebe\u011fe a\u015f\u0131 uyguland\u0131\u011f\u0131nda nas\u0131l bir imm&uuml;nolojik cevap al\u0131naca\u011f\u0131, bu uygulaman\u0131n k\u0131sa ve uzun vadeli yan etkilerinin ne olaca\u011f\u0131, do\u011fumdan sonra geli\u015fimi devam eden imm&uuml;n sistem, sinir sistemi ve mikrobiom &uuml;zerine ne gibi etkileri olaca\u011f\u0131 konusunda hemen hi&ccedil; bilgimiz yoktur. Bunlar hakk\u0131nda yeterli bilgi oldu\u011fu, uygulanmakta olan a\u015f\u0131lar\u0131n maksad\u0131 h&acirc;s\u0131l ederken zarar verip vermedi\u011fi de me&ccedil;huld&uuml;r&rdquo;. <\/span><\/em><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Alt\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> &Ccedil;ocuk sa\u011fl\u0131\u011f\u0131 ve hastal\u0131klar\u0131 uzman\u0131 Prof. Dr. Ahmet Ayd\u0131n da <strong>&ldquo;Otizme &Ccedil;&ouml;z&uuml;m Var&rdquo;<\/strong> isimli kitab\u0131nda \u015funlar\u0131 s&ouml;ylemektedir: <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><em><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">&ldquo;K\u0131zam\u0131k-k\u0131zam\u0131k&ccedil;\u0131k-kabakulak a\u015f\u0131s\u0131 timerosal i&ccedil;ermese de otizme neden olabilir. Bunun temel nedeni otizme e\u011filimi olan &ccedil;ocu\u011fun ba\u011f\u0131\u015f\u0131kl\u0131k sisteminde olan yetersizlik halidir. Normalde ba\u011f\u0131rsaktaki faydal\u0131 mikroplar (probiyotikler) Th1 ad\u0131 verilen ba\u011f\u0131\u015f\u0131kl\u0131k h&uuml;crelerinin yolunu uyar\u0131r. Bu yolun uyar\u0131lmas\u0131 mantarlar ve vir&uuml;slerin v&uuml;cuttan uzakla\u015ft\u0131r\u0131lmas\u0131n\u0131 sa\u011flar. Sezaryen do\u011fum, anne s&uuml;t&uuml;n&uuml;n kullan\u0131lmamas\u0131, do\u011fal olmayan katk\u0131l\u0131 g\u0131dalar\u0131n a\u015f\u0131r\u0131 t&uuml;ketilmesi, ek\u015fimeyen yo\u011furtlar\u0131n ve kaymak ba\u011flamayan past&ouml;rize ya da UHT teknolojisiyle &uuml;retilmi\u015f s&uuml;tlerin t&uuml;ketilmesi, geleneksel fermente g\u0131dalar\u0131n (kefir, yo\u011furt, tur\u015fu, sirke vb) az t&uuml;ketilmesi ve s\u0131k antibiyotik kullan\u0131lmas\u0131 ba\u011f\u0131rsaktaki faydal\u0131 mikrop d&uuml;zenini b&uuml;y&uuml;k &ouml;l&ccedil;&uuml;de alt &uuml;st eder. Bu s\u0131rada Th2 yolu ise a\u015f\u0131r\u0131 uyar\u0131l\u0131r; sonu&ccedil;ta ba\u011f\u0131rsak ge&ccedil;irgenli\u011fi artar, baz\u0131 maddeler ba\u011f\u0131rsaktan kana sindirilmeden ge&ccedil;er. V&uuml;cut taraf\u0131ndan d&uuml;\u015fman olarak alg\u0131lanan bu maddeler ba\u011f\u0131\u015f\u0131kl\u0131k sistemi taraf\u0131ndan tahrip edilir. Bu s\u0131rada sa\u011flam dokular da bundan zarar g&ouml;r&uuml;r. Ast\u0131m, egzama, tiroidit ve &ccedil;e\u015fitli otoimm&uuml;n hastal\u0131klar olu\u015fur. Th1 yolunun yetersiz uyar\u0131lmas\u0131 halinde v&uuml;cut mantarlar ve vir&uuml;sler ile gere\u011fi gibi m&uuml;cadele edemez. Bu nedenle K\u0131zam\u0131k-k\u0131zam\u0131k&ccedil;\u0131k-kabakulak a\u015f\u0131s\u0131ndaki 3 canl\u0131 vir&uuml;s ile birden ba\u015f edemez. Yine ayn\u0131 nedenden dolay\u0131 otistik &ccedil;ocuklarda mantar enfeksiyonlar\u0131 ve alerjik hastal\u0131klar s\u0131kt\u0131r. Bu nedenle k\u0131zam\u0131k a\u015f\u0131s\u0131 tek olarak yap\u0131lmal\u0131d\u0131r. K\u0131zam\u0131k&ccedil;\u0131k ve kabakulak hastal\u0131klar\u0131 hafif ge&ccedil;irildi\u011fi i&ccedil;in bu hastal\u0131klara kar\u015f\u0131 a\u015f\u0131lanma gerekmez. Ama maalesef piyasada art\u0131k k\u0131zam\u0131k a\u015f\u0131s\u0131 tek olarak bulunmamaktad\u0131r. Hayat\u0131n ilk 2-3 haftas\u0131 i&ccedil;inde sa\u011fl\u0131kl\u0131 bir floran\u0131n olu\u015fmamas\u0131 bebe\u011fin ba\u011f\u0131\u015f\u0131kl\u0131k sistemini ciddi \u015fekilde etkiler. Bu tip bebeklerin (&ouml;zellikle sezaryen ile do\u011fanlar\u0131n) ba\u011f\u0131\u015f\u0131kl\u0131k sistemi standart a\u015f\u0131lama program\u0131na uygun de\u011fildir ve ciddi sorunlara yol a&ccedil;abilir. H&acirc;lbuki sa\u011fl\u0131kl\u0131 floras\u0131 olan &ccedil;ocuklarda &ouml;nemli bir sorun olmaz.&rdquo;<\/span><\/em><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 14pt; font-family: Arial, sans-serif;\">Belli bir risk yoksa 2 ya\u015f\u0131na kadar hi&ccedil; a\u015f\u0131 yapmamak en iyisidir. <\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Ama e\u011fer anne Hepatit B ta\u015f\u0131y\u0131c\u0131s\u0131 ise bu s&uuml;re i&ccedil;inde a\u015f\u0131s\u0131 yap\u0131lmal\u0131d\u0131r. Ayr\u0131ca yak\u0131n &ccedil;evrede bo\u011fmaca, k\u0131zam\u0131k ve &ccedil;ocuk felci gibi a\u015f\u0131yla &ouml;nlenebilen bir hastal\u0131k salg\u0131n\u0131 varsa bu a\u015f\u0131lar mutlaka iki ya\u015f\u0131ndan &ouml;nce yap\u0131lmal\u0131d\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Yedi:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Say\u0131s\u0131z ara\u015ft\u0131rma ve vaka bildirilerinde a\u015f\u0131lamadan sonra artrit, vask&uuml;lit, ensefalit, n&ouml;ropati ve demiyelinasyon ba\u015fta olmak &uuml;zere oto-antikor ve oto-imm&uuml;n fenomenlerin g&ouml;r&uuml;ld&uuml;\u011f&uuml; iyi bilinir ama illiyet kriterleri maalesef iyi tan\u0131mlanm\u0131\u015f de\u011fildir. Bununla beraber, oto-imm&uuml;niteyi tetikleyen fakt&ouml;rlerin ba\u015f\u0131nda enfeksiyon ajanlar\u0131 gelir ve a\u015f\u0131larda bulunan ajanlara ait antijenler &ldquo;molecular mimicry&rdquo;, &ldquo;epitope spreading&rdquo;, &ldquo;bystander activation&rdquo; ve &ldquo;polyclonal activation&rdquo; gibi benzer mekanizmalarla oto-imm&uuml;niteye yol a&ccedil;abilirler. \u0130mm&uuml;n sistemi uyarmak i&ccedil;in kullan\u0131lan adjuvanlar, bir dizi geni, antijen sunan h&uuml;crelerin g&ouml;&ccedil;&uuml;n&uuml; mod&uuml;le edebilir ve PAMPS gibi molek&uuml;lleri spesifik olarak taklit ederek &ldquo;innate&rdquo; ve &ldquo;adaptif imm&uuml;n cevaplar\u0131&rdquo; art\u0131rabilir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">A\u015f\u0131larda bulunan adjuvanlarla ilgili olarak ortaya &ccedil;\u0131kan oto-imm&uuml;n sendromlar bilimsel literat&uuml;rde ASIA yani &#8220;Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants&#8221; ad\u0131yla tan\u0131mlanm\u0131\u015ft\u0131r. A\u015f\u0131lar hipersensitivite, enfeksiyon ind&uuml;ksiyonu ve oto-imm&uuml;niteye yol a&ccedil;abilirler, bunlar a\u011f\u0131r ve hatta &ouml;l&uuml;mc&uuml;l de olabilir. A\u015f\u0131lama sonras\u0131 oto-imm&uuml;n fenomenlerin nadir olmalar\u0131 ve subakut ortaya &ccedil;\u0131kmalar\u0131 sebebiyle illiyeti g&ouml;stermek zordur. Ayr\u0131ca, a\u015f\u0131lama ve oto-imm&uuml;nite aras\u0131ndaki latent d&ouml;nem g&uuml;nler-seneler aras\u0131nda de\u011fi\u015fir. A\u015f\u0131larda bulunan katk\u0131 maddeleri listesine bakmak da yeterli fikir verecektir. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Sekiz:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> USA&rsquo;da Y&uuml;ksek Mahkeme (Supreme Court) 2011&rsquo;de a\u015f\u0131lar\u0131 <strong>&lsquo;Ka&ccedil;\u0131n\u0131lmaz Olarak Emniyetsiz&rsquo; (Unavoidably Unsafe)<\/strong> ilan etmi\u015f, a\u015f\u0131dan zarar g&ouml;rd&uuml;\u011f&uuml;n&uuml; iddia eden bir kimsenin &ldquo;&uuml;reticiye kar\u015f\u0131 dava a&ccedil;amayaca\u011f\u0131na&rdquo; ve a\u015f\u0131lar\u0131n sebep olabilece\u011fi risklerin tamamen aileler taraf\u0131ndan &uuml;stlenilmesi gerekti\u011fine karar vermi\u015ftir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Buna kar\u015f\u0131l\u0131k Avrupa Birli\u011fi Adalet Divan\u0131, mahkemelerin aralar\u0131ndaki ili\u015fkiyi teyit eden bilimsel deliller olmadan da a\u015f\u0131lar\u0131n bir hastal\u0131\u011f\u0131n sebebi olabilece\u011fi iddialar\u0131n\u0131 dikkate almalar\u0131na h&uuml;kmetti. Avrupa Birli\u011fi&rsquo;nin bu en y&uuml;ksek yarg\u0131 kurumu, bir ki\u015finin hastal\u0131\u011f\u0131n\u0131n a\u015f\u0131dan k\u0131sa s&uuml;re sonra ortaya &ccedil;\u0131kmas\u0131 ve daha &ouml;nce sa\u011fl\u0131kl\u0131 olmas\u0131, ailesinde b&ouml;yle bir hastal\u0131k olmamas\u0131 ve yeteri kadar benzeri vaka bulunmas\u0131n\u0131, a\u015f\u0131lar\u0131 su&ccedil;lamak i&ccedil;in yeterli olaca\u011f\u0131n\u0131 bildirmektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Dokuz:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Halk sa\u011fl\u0131\u011f\u0131 hocalar\u0131ndan Prof. Dr. Gazanfer Aksako\u011flu&rsquo;nun &ldquo;Uluslararas\u0131 sermaye ve ba\u011f\u0131\u015f\u0131klama pazar\u0131&rdquo; ba\u015fl\u0131kl\u0131 makalesini de bir kere daha hat\u0131rlat\u0131yorum: <strong><em>&ldquo;Ba\u011f\u0131\u015f\u0131klama da, a\u015f\u0131 &uuml;retimi de devletin elinden ve kamu g&ouml;revi olmaktan &ccedil;\u0131kar\u0131ld\u0131, sermayeye teslim edilerek tatl\u0131 k&acirc;rlar i&ccedil;in yat\u0131r\u0131m arac\u0131na d&ouml;n&uuml;\u015ft&uuml;r&uuml;ld&uuml;. Art\u0131k bebeklerin ve eri\u015fkinlerin ba\u011f\u0131\u015f\u0131klanmalar\u0131 &uuml;zerinde ki\u015fisel, kurumsal ve s\u0131n\u0131fsal &ccedil;at\u0131\u015fmalar, uluslararas\u0131 sermayenin kanl\u0131 &ccedil;\u0131kar oyunlar\u0131 yer al\u0131yor&rdquo;.<\/em><\/strong><\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">On: <\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">1985&rsquo;te CDC taraf\u0131ndan tavsiye edilen a\u015f\u0131lar\u0131n maliyeti 80 dolar iken, bug&uuml;n neredeyse 30 misli aratarak 2200 dolara y&uuml;kselmi\u015ftir. BBC&rsquo;nin bir haberinde Avrupa Parlamentosu&rsquo;na sunulan bir rapor, bir &ccedil;ocuk i&ccedil;in tam bir a\u015f\u0131 paketinin fiyat\u0131n\u0131n 2001 ile 2014 aras\u0131nda 68 kat artt\u0131\u011f\u0131n\u0131 bildirmi\u015ftir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">On Bir:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> 2004&rsquo;te, a\u015f\u0131lar ile ilgili en muteber dergi olan Vaccine&rsquo;de yay\u0131nlanan makalede, toplumsal a\u015f\u0131lama ile ilgili belirlenen 7 ilkeden birincisinin &lsquo;toplumsal sa\u011fl\u0131\u011f\u0131 tehdit eden hastal\u0131klar\u0131n hedef al\u0131nmas\u0131&rsquo; oldu\u011funu bildirmi\u015ftir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Buna g&ouml;re, mortalitenin yani &ouml;l&uuml;m oran\u0131n\u0131n y&uuml;zde 0.12&rsquo;den y&uuml;ksek olmas\u0131 gerekmektedir ki &ccedil;ocuk a\u015f\u0131 takvimindeki a\u015f\u0131lar\u0131n &ccedil;o\u011fu bu ilkeye terstir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">On \u0130ki: <\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Yale ve Pennsylvania State T\u0131p Fak&uuml;lteleri uzmanlar\u0131nca ger&ccedil;ekle\u015ftirilen ara\u015ft\u0131rmada baz\u0131 beyin hastal\u0131klar\u0131n\u0131n ba\u015flang\u0131c\u0131n\u0131n bir grup &ccedil;ocukta daha &ouml;nce yap\u0131lan a\u015f\u0131lar\u0131n zamanlamas\u0131yla ilgili olabilece\u011fi tespit edilmi\u015ftir. 6-15 ya\u015f aras\u0131ndaki &ccedil;ocuklara ait be\u015f senelik sa\u011fl\u0131k sigortas\u0131 verilerinden yararlan\u0131larak yap\u0131lan &ccedil;al\u0131\u015fmada baz\u0131 n&ouml;ro-psikiyatrik hastal\u0131klar\u0131n te\u015fhisinin 3-12 ay &ouml;nce a\u015f\u0131 yap\u0131lan &ccedil;ocuklarda a\u015f\u0131 yap\u0131lmayanlara nazaran daha fazla oldu\u011fu belirlenmi\u015ftir. Analizlerde, a\u015f\u0131lanan &ccedil;ocuklarda anoreksiya nervosa te\u015fhisi a\u015f\u0131lanmayan &ccedil;ocuklara oranla y&uuml;zde 80 ve obsesif komp&uuml;lsif hastal\u0131k te\u015fhisi y&uuml;zde 25 fazla bulundu. A\u015f\u0131 yap\u0131lan &ccedil;ocuklarda anksiyete hastal\u0131\u011f\u0131 ve tik hastal\u0131\u011f\u0131 riski de a\u015f\u0131lanmayanlara g&ouml;re daha y&uuml;ksekti. Beklenildi\u011fi gibi, a&ccedil;\u0131k yara ve kemik k\u0131r\u0131\u011f\u0131 ile a\u015f\u0131lamalar aras\u0131nda herhangi bir ili\u015fki bulunmazken yeni maj&ouml;r depresyon, bipolar hastal\u0131k veya DEHH aras\u0131nda da bir ili\u015fki ortaya konamad\u0131. Bu t&uuml;r, a\u015f\u0131lar\u0131n (veya ila&ccedil;lar\u0131n veya di\u011fer t\u0131bbi m&uuml;dahalelerin) birtak\u0131m olumsuzluklar\u0131 olabilece\u011fini ortaya koyan ara\u015ft\u0131rmalar bilim d&uuml;nyas\u0131nda genelde g&ouml;rmezden gelinmeye &ccedil;al\u0131\u015f\u0131l\u0131r, medyada haber olarak pek yer almaz. Tam tersi bir sonu&ccedil; &ccedil;\u0131km\u0131\u015f olsayd\u0131 ara\u015ft\u0131rma medyada y&uuml;zlerce habere konu olurdu.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">On &Uuml;&ccedil;:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131 say\u0131s\u0131 artt\u0131k&ccedil;a hastal\u0131klar\u0131n ve bunlara ba\u011fl\u0131 komplikasyon ve &ouml;l&uuml;mlerin azalaca\u011f\u0131 d&uuml;\u015f&uuml;n&uuml;lebilir, ama bunun do\u011fru olmayabilece\u011fini g&ouml;steren, &ldquo;end&uuml;stri ile menfaat m&uuml;nasebeti olmayan ba\u011f\u0131ms\u0131z uzmanlar taraf\u0131ndan&rdquo; ger&ccedil;ekle\u015ftirilen &ouml;nemli bir ara\u015ft\u0131rma vard\u0131r. USA ki\u015fi ba\u015f\u0131na en &ccedil;ok sa\u011fl\u0131k harcamas\u0131n\u0131 yapan ve 1 ya\u015f\u0131ndan k&uuml;&ccedil;&uuml;k bebeklere 26 a\u015f\u0131 yap\u0131lan tek &uuml;lke olmakla beraber, daha az a\u015f\u0131 uygulanan 33 &uuml;lkede &ldquo;bebek &ouml;l&uuml;m oranlar\u0131 (IMR)&rdquo; USA&rsquo;dan daha d&uuml;\u015f&uuml;kt&uuml;r. USA&rsquo;da 2 ya\u015f\u0131na kadar 14 etkene ait toplam 26 doz, 6 ya\u015f\u0131na kadar toplam 49 doz, 18 ya\u015f\u0131na kadar ise 16 etkene ait a\u015f\u0131lardan toplam 69 doz uygulan\u0131yor. IMR, Singapur ve \u0130sve&ccedil;&rsquo;te USA&rsquo;dakinin yar\u0131s\u0131ndan azd\u0131r ve Japonya&rsquo;da 2.80&rsquo;in de alt\u0131ndad\u0131r. CDC&rsquo;ye g&ouml;re USA&rsquo;da durum daha da k&ouml;t&uuml;le\u015fmektedir. Bu ara\u015ft\u0131rmadan, daha &ccedil;ok a\u015f\u0131n\u0131n daha az bebek &ouml;l&uuml;m&uuml; demek olmad\u0131\u011f\u0131 sonucu ortaya &ccedil;\u0131k\u0131yor.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">On D&ouml;rt:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> 2009&rsquo;da 34 &uuml;lke i&ccedil;inde en d&uuml;\u015f&uuml;k IMR sahip olan be\u015f &uuml;lkede 1 ya\u015f\u0131na kadar sadece 12 doz a\u015f\u0131 yap\u0131lmakta iken bu oran USA&rsquo;da 26&rsquo;d\u0131r. Enfeksiyonlardan korunmada esas &ouml;nemli olan temiz su, kanalizasyon, hijyen, uygun beslenme ve sa\u011fl\u0131k kurulu\u015flar\u0131na eri\u015fim gibi fakt&ouml;rlerdir. Gambia&rsquo;da bebeklik &ccedil;a\u011f\u0131nda 22 doz a\u015f\u0131 y&uuml;zde 91-97 oran\u0131nda uygulanmas\u0131na kar\u015f\u0131l\u0131k IMR&rsquo;nin 68.8 ve 22 doz a\u015f\u0131n\u0131n y&uuml;zde 95-98 oran\u0131nda uyguland\u0131\u011f\u0131 Mo\u011folistan&rsquo;da 39.9 olmas\u0131, tek ba\u015f\u0131na a\u015f\u0131laman\u0131n IMR&rsquo;ye etkisinin olmad\u0131\u011f\u0131n\u0131 g&ouml;sterir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Ani bebek &ouml;l&uuml;m&uuml; sendromu (SIDS)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> ile a\u015f\u0131lar aras\u0131nda herhangi bir korelasyon olmad\u0131\u011f\u0131n\u0131 bildiren ara\u015ft\u0131rmalar bulunmakla beraber, baz\u0131 bebeklerin SIDS&rsquo;a daha duyarl\u0131 olabilece\u011fi sonucuna varan ara\u015ft\u0131rmalar da vard\u0131r. Bu bilgiler, &ccedil;ocuk sa\u011fl\u0131\u011f\u0131 ve &uuml;lkelerin genel geli\u015fmi\u015fli\u011fini g&ouml;steren en &ouml;nemli &ouml;l&ccedil;&uuml;lerden biri olan bebek &ouml;l&uuml;m oranlar\u0131n\u0131n (IMR) a\u015f\u0131lama ile do\u011frudan bir ili\u015fkisi olmad\u0131\u011f\u0131n\u0131n, hatta a\u015f\u0131 say\u0131s\u0131n\u0131 art\u0131rman\u0131n faydadan ziyade zarar getirebilece\u011finin de bir g&ouml;stergesidir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">On Be\u015f:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> USA&rsquo;da &ccedil;ocuklarda a\u015f\u0131 takvimiyle ilgili soru ve endi\u015felerin &ccedil;\u0131\u011f gibi artmas\u0131 &uuml;zerine, k\u0131sa ad\u0131 IOM olan T\u0131p Enstit&uuml;s&uuml; (The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence and Future) literat&uuml;rde a\u015f\u0131lar\u0131n emniyeti ile ilgili bilimsel ara\u015ft\u0131rmalar\u0131 &ccedil;ok teferruatl\u0131 olarak de\u011ferlendirme ihtiyac\u0131 duymu\u015f ve bunu 2013&rsquo;te &ldquo;The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence and Future Studies&rdquo; ad\u0131yla yay\u0131nlam\u0131\u015ft\u0131r. Bu rapor a\u015f\u0131 takviminin &ldquo;tart\u0131\u015f\u0131lmas\u0131&rdquo; gerekti\u011fini a&ccedil;\u0131k ve net olarak ortaya koymaktad\u0131r. IOM Komitesi 2003&rsquo;ten o tarihe kadar 40 kadar yay\u0131n bulabilmi\u015f ve bilimsel olarak a\u015f\u0131 takviminin emniyeti ile al&acirc;kal\u0131 &ccedil;ok &ouml;nemli bo\u015fluklar oldu\u011funu bildirmi\u015ftir. Buna g&ouml;re, a\u015f\u0131lama takviminde yer alan a\u015f\u0131lar\u0131n say\u0131s\u0131, s\u0131kl\u0131\u011f\u0131, zamanlamas\u0131, s\u0131ras\u0131 ve uygulama ya\u015f\u0131 ara\u015ft\u0131rmalarda sistematik olarak incelenmemi\u015ftir. CDC taraf\u0131ndan 6 ya\u015f\u0131ndan &ouml;nce tavsiye edilen a\u015f\u0131lar\u0131n say\u0131s\u0131 ve zamanlamas\u0131n\u0131n premat&uuml;re bebeklerde sa\u011fl\u0131k sorunlar\u0131na ve &ccedil;ocuklarda ast\u0131m, atopi, alerji, otoimm&uuml;nite, otizm, &ouml;\u011frenme hastal\u0131klar\u0131, dikkat eksikli\u011fi, havale gibi kronik beyin ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemi hastal\u0131klar\u0131na yol a&ccedil;\u0131p a&ccedil;mad\u0131\u011f\u0131 belirlenememi\u015ftir. Biyolojik olarak a\u015f\u0131lara ba\u011fl\u0131 zarar ve &ouml;l&uuml;m riski y&uuml;ksek olan duyarl\u0131 &ccedil;ocuklar i&ccedil;in de &ccedil;ok s\u0131n\u0131rl\u0131 bilgi vard\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">On Alt\u0131:<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> K\u0131sa ad\u0131 NVIC olan National Vaccine Information Center da bir bildiri yay\u0131nlayarak gelecekte a\u015f\u0131lanan ve a\u015f\u0131lanmayan &ccedil;ocuklardaki ve alternatif a\u015f\u0131lama takvimi uygulananlardaki sa\u011fl\u0131k sonu&ccedil;lar\u0131n\u0131 da kapsayan federal a\u015f\u0131lama politikalar\u0131n\u0131n emniyetini de\u011ferlendirecek olan ara\u015ft\u0131rmalar\u0131n \u015feffafl\u0131\u011f\u0131, ba\u011f\u0131ms\u0131zl\u0131\u011f\u0131 ve tekrarlanabilir olmas\u0131na vurgu yapm\u0131\u015ft\u0131r. NVIC; hi&ccedil; a\u015f\u0131lanmam\u0131\u015f &ccedil;ocuklarla, h&uuml;k&uuml;metin tavsiyesi olan t&uuml;m a\u015f\u0131lar\u0131n yap\u0131lm\u0131\u015f oldu\u011fu &ccedil;ocuklardaki sa\u011fl\u0131k sonu&ccedil;lar\u0131n\u0131 kar\u015f\u0131la\u015ft\u0131ran hi&ccedil;bir &ccedil;al\u0131\u015fma olmad\u0131\u011f\u0131na da dikkat &ccedil;ekmektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">Gelelim neticeye:<\/span><\/strong><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">a)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131lar, sahtek&acirc;rl\u0131ktan h&uuml;k&uuml;ml&uuml;, esas amac\u0131 daha &ccedil;ok k&acirc;r etmek olan ila&ccedil; end&uuml;strisinin inisiyatifine teslim edilmeyecek kadar hayati &uuml;r&uuml;nlerdir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">b)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131lar hakk\u0131nda birtak\u0131m endi\u015felerini dile getiren bilim adamlar\u0131 a\u015f\u0131lara de\u011fil bunlar\u0131n gereksiz olanlar\u0131na kar\u015f\u0131d\u0131r ve k&uuml;&ccedil;&uuml;k &ccedil;ocuklara yap\u0131lan ve say\u0131lar\u0131 her ge&ccedil;en g&uuml;n artan a\u015f\u0131lardan endi\u015fe duymaktad\u0131r.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">c)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131lar\u0131n endikasyon, etkinlik ve emniyetleri ile ilgili meseleleri, gerek&ccedil;eleri ve bilimsel kaynaklar\u0131 ile ortaya koyan bilim adamlar\u0131 end&uuml;striyi dellendirmektedir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">d)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131lar tart\u0131\u015f\u0131lmamal\u0131d\u0131r diyen, a\u015f\u0131larla ilgili her tenkidi a\u015f\u0131 kar\u015f\u0131tl\u0131\u011f\u0131 ile su&ccedil;layan end&uuml;stri, yeni a\u015f\u0131lar\u0131n\u0131 istedi\u011fi gibi dayatamama endi\u015fesindendir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">e)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> &ldquo;A\u015f\u0131lar tart\u0131\u015f\u0131lamaz-tart\u0131\u015f\u0131lmamal\u0131d\u0131r&rdquo; s&ouml;z&uuml;n&uuml;n arkas\u0131nda halk\u0131n sa\u011fl\u0131\u011f\u0131 de\u011fil, her &ccedil;\u0131kan yeni a\u015f\u0131n\u0131n t&uuml;m d&uuml;nyaya zorunlu a\u015f\u0131 olarak kabul ettirilmesi, ila&ccedil; \u015firketlerinin menfaati gere\u011fidir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">f)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> End&uuml;strinin derdi asla k\u0131zam\u0131k, bo\u011fmaca salg\u0131n\u0131 falan de\u011fildir, onlar\u0131n t&uuml;m kayg\u0131s\u0131 yeni a\u015f\u0131lar\u0131na pazar &uuml;retmektir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">g)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Kimsenin hi&ccedil; itiraz etmedi\u011fi a\u015f\u0131lar\u0131 &ouml;rnek g&ouml;stererek t&uuml;m a\u015f\u0131lar\u0131 ayn\u0131 gereklilik, etkinlik ve emniyette g&ouml;stermek yanl\u0131\u015f ve &uuml;stelik de tehlikelidir: Bu, kurnaz t&uuml;ccarlar\u0131n i\u015fidir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">h)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131lar\u0131 kategorik olarak desteklemek de kar\u015f\u0131 &ccedil;\u0131kmak da ayn\u0131 \u015fekilde yanl\u0131\u015f ve tehlikelidir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">i)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> Her a\u015f\u0131, ticari bir &uuml;r&uuml;n olduklar\u0131 hakikati unutulmadan ayr\u0131 ayr\u0131 de\u011ferlendirilmelidir.<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\">j)<\/span><\/strong><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"> A\u015f\u0131lar, t\u0131pk\u0131 silahlar gibidir, stratejik &uuml;r&uuml;nlerdir, bunlar\u0131 kendimiz &uuml;retmeliyiz. 30 sene &ouml;ncesine kadar kendi a\u015f\u0131m\u0131z\u0131 &uuml;retirken ve hatta ba\u015fka memleketlere de ihra&ccedil; ederken, neden bundan vazge&ccedil;tik veya vazge&ccedil;irildik?<\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; text-align: justify; text-indent: 1cm; line-height: 16pt;\"><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"><\/span><span style=\"font-size: 12pt; font-family: Arial, sans-serif;\"><\/span><\/p>\n<p>&nbsp;<\/p>\n<p>Bu makaleyi sesli olarak dinleyebilirsiniz:<\/p>\n<p>{mp3}asilar_saglikli_mi{\/mp3}<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom: .0001pt; text-align: justify; text-justify: inter-ideograph; text-indent: 1.0cm; line-height: 16.0pt;\">&nbsp;<\/p>\n<hr style=\"text-align: left;\" size=\"1\" width=\"33%\" \/>\n<p><a href=\"#ftnref1\" id=\"ftn1\" style=\"vertical-align: super;\">[1]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Kaynak: Vaccine Epidemic Sf. 60<\/span><\/p>\n<p><a href=\"#ftnref2\" id=\"ftn2\" style=\"vertical-align: super;\">[2]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Volk WA, et al. Basic Microbiology, 4th edition. Philadelphia, PA: J.B. Lippincott Co., 1980:455.<\/span><\/p>\n<p><a href=\"#ftnref3\" id=\"ftn3\" style=\"vertical-align: super;\">[3]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Physician&rsquo;s Desk Reference (PDR); 55th edition.<\/span><\/p>\n<p><a href=\"#ftnref4\" id=\"ftn4\" style=\"vertical-align: super;\">[4]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Physician&rsquo;s Desk Reference (PDR); 55 th edition. Montvale, NJ: Medical Economics, 2001:778. <\/span><\/p>\n<p><a href=\"#ftnref5\" id=\"ftn5\" style=\"vertical-align: super;\">[5]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Moskowitz R. Immunizations: The Other Side.Mothering Spring 1984:36.<\/span><\/p>\n<p><a href=\"#ftnref6\" id=\"ftn6\" style=\"vertical-align: super;\">[6]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Harry NM. The recovery period in anterior poliomyelitis. British Medical Journal 1938; 1:164&ndash;7. <\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; line-height: normal;\"><a href=\"#ftnref7\" id=\"ftn7\" style=\"vertical-align: super;\">[7]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> &Ccedil;eviren: &Ouml;zgecan Kocaman Kaynak: Asymptomatic transmission and the resurgence of Bordetella pertussis.<\/span><\/p>\n<p><a href=\"#ftnref8\" id=\"ftn8\" style=\"vertical-align: super;\">[8]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> <span style=\"text-decoration: none;\"><a href=\"http:\/\/www.globalresearch.ca\/vaccines-u-s-centers-for-disease\"><span style=\"text-decoration: none;\">http:\/\/www.globalresearch.ca\/vaccines-u-s-centers-for-disease<\/span><\/a><\/span><\/span><\/p>\n<p><a href=\"#ftnref9\" id=\"ftn9\" style=\"vertical-align: super;\">[9]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> <span style=\"text-decoration: none;\"><a href=\"http:\/\/www.globalresearch.ca\/cnn-complicit-in-media-coverup-of-u-s-centers-for-disease-control-vaccine-fraud\/5397592\"><span style=\"text-decoration: none;\">http:\/\/www.globalresearch.ca\/cnn-complicit-in-media-coverup-of-u-s-centers<\/span><\/a><\/span><\/span><\/p>\n<p><a href=\"#ftnref10\" id=\"ftn10\" style=\"vertical-align: super;\">[10]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Arama motoruna &lsquo;Hooker&rsquo; &lsquo;a\u015f\u0131&rsquo; &lsquo;CDC&rsquo; yaz\u0131p T&uuml;rk&ccedil;e sonu&ccedil;lar\u0131 aray\u0131n.<\/span><\/p>\n<p><a href=\"#ftnref11\" id=\"ftn11\" style=\"vertical-align: super;\">[11]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> <span style=\"text-decoration: none;\"><a href=\"http:\/\/www.globalresearch.ca\/autism-links-to-vaccines-whistleblower-reveals-evidence-of-criminal-coverup-by-the-centers-for-disease-control-cdc\/5397928\"><span style=\"text-decoration: none;\">http:\/\/www.globalresearch.ca\/autism-links-to-vaccines-whistleblower-reveals-evidence-of-criminal<\/span><\/a><\/span><\/span><\/p>\n<p><a href=\"#ftnref12\" id=\"ftn12\" style=\"vertical-align: super;\">[12]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> <span style=\"text-decoration: none;\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25114790\"><span style=\"text-decoration: none;\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25114790<\/span><\/a><\/span><\/span><\/p>\n<p><a href=\"#ftnref13\" id=\"ftn13\" style=\"vertical-align: super;\">[13]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> <span style=\"text-decoration: none;\"><a href=\"http:\/\/en.wikipedia.org\/wiki\/Julie_Gerberding\"><span style=\"text-decoration: none;\">http:\/\/en.wikipedia.org\/wiki\/Julie_Gerberding<\/span><\/a><\/span><\/span><\/p>\n<p><a href=\"#ftnref14\" id=\"ftn14\" style=\"vertical-align: super;\">[14]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> <span style=\"text-decoration: none;\"><a href=\"http:\/\/ahmetrasimkucukusta.com\/2014\/05\/18\/misafir-yazar\/kizamik-virusu-bagisiklik-sistemini-nasil-etkiler\/\"><span style=\"text-decoration: none;\">http:\/\/ahmetrasimkucukusta.com\/2014\/05\/18\/misafir-yazar\/kizamik-virusu-bagisiklik-sistemini<\/span><\/a><\/span><\/span><\/p>\n<p><a href=\"#ftnref15\" id=\"ftn15\" style=\"vertical-align: super;\">[15]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> <span style=\"text-decoration: none;\"><a href=\"http:\/\/www.asicalismagrubu.org\/acg4.asp\"><span style=\"text-decoration: none;\">http:\/\/www.asicalismagrubu.org\/acg4.asp<\/span><\/a><\/span><\/span><\/p>\n<p><a href=\"#ftnref16\" id=\"ftn16\" style=\"vertical-align: super;\">[16]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> Prof. Dr. Ali\u015fan Y\u0131ld\u0131ran <span style=\"text-decoration: none;\"><a href=\"http:\/\/ahmetrasimkucukusta.com\/2014\/08\/30\/misafir-yazar\/asi\/skandal%C4%B1\/\"><span style=\"text-decoration: none;\">http:\/\/ahmetrasimkucukusta.com\/2014\/08\/30\/misafir-yazar\/asi\/skandal\u0131\/<\/span><\/a><\/span><\/span><\/p>\n<p style=\"margin-bottom: 0.0001pt; line-height: normal;\"><a href=\"#ftnref17\" id=\"ftn17\" style=\"vertical-align: super;\">[17]<\/a><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> 15 Nisan 2018 Pazar <span style=\"text-decoration: none;\">http:\/\/www.cumhuriyet.com.tr<\/span><\/span><\/p>\n<p> <!-- [if gte mso 9]><xml>  <o:OfficeDocumentSettings>   <o:RelyOnVML\/>   <o:AllowPNG\/>  <\/o:OfficeDocumentSettings> <\/xml><![endif]--><!-- [if gte mso 9]><xml>  <w:WordDocument>   <w:View>Normal<\/w:View>   <w:Zoom>0<\/w:Zoom>   <w:TrackMoves\/>   <w:TrackFormatting\/>   <w:DoNotShowComments\/>   <w:DoNotShowPropertyChanges\/>   <w:HyphenationZone>21<\/w:HyphenationZone>   <w:PunctuationKerning\/>   <w:ValidateAgainstSchemas\/>   <w:SaveIfXMLInvalid>false<\/w:SaveIfXMLInvalid>   <w:IgnoreMixedContent>false<\/w:IgnoreMixedContent>   <w:AlwaysShowPlaceholderText>false<\/w:AlwaysShowPlaceholderText>   <w:DoNotPromoteQF\/>   <w:LidThemeOther>TR<\/w:LidThemeOther>   <w:LidThemeAsian>X-NONE<\/w:LidThemeAsian>   <w:LidThemeComplexScript>X-NONE<\/w:LidThemeComplexScript>   <w:Compatibility>    <w:BreakWrappedTables\/>    <w:SnapToGridInCell\/>    <w:WrapTextWithPunct\/>    <w:UseAsianBreakRules\/>    <w:DontGrowAutofit\/>    <w:SplitPgBreakAndParaMark\/>    <w:EnableOpenTypeKerning\/>    <w:DontFlipMirrorIndents\/>    <w:OverrideTableStyleHps\/>    <w:UseFELayout\/>   <\/w:Compatibility>   <m:mathPr>    <m:mathFont m:val=\"Cambria Math\"\/>    <m:brkBin m:val=\"before\"\/>    <m:brkBinSub m:val=\"&#45;-\"\/>    <m:smallFrac m:val=\"off\"\/>    <m:dispDef\/>    <m:lMargin m:val=\"0\"\/>    <m:rMargin m:val=\"0\"\/>    <m:defJc m:val=\"centerGroup\"\/>    <m:wrapIndent m:val=\"1440\"\/>    <m:intLim m:val=\"subSup\"\/>    <m:naryLim m:val=\"undOvr\"\/>   <\/m:mathPr><\/w:WordDocument> <\/xml><![endif]--><!-- [if gte mso 9]><xml>  <w:LatentStyles DefLockedState=\"false\" DefUnhideWhenUsed=\"false\"   DefSemiHidden=\"false\" DefQFormat=\"false\" DefPriority=\"99\"   LatentStyleCount=\"375\">   <w:LsdException Locked=\"false\" Priority=\"0\" QFormat=\"true\" Name=\"Normal\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" QFormat=\"true\" Name=\"heading 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 7\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 8\"\/>   <w:LsdException Locked=\"false\" Priority=\"9\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"heading 9\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 7\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 8\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index 9\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 7\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 8\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"toc 9\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Normal Indent\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"footnote text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"annotation text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"header\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"footer\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"index heading\"\/>   <w:LsdException Locked=\"false\" Priority=\"35\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"caption\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"table of figures\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"envelope address\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"envelope return\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"footnote reference\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"annotation reference\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"line number\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"page number\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"endnote reference\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"endnote text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"table of authorities\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"macro\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"toa heading\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Bullet 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Number 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"10\" QFormat=\"true\" Name=\"Title\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Closing\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Signature\"\/>   <w:LsdException Locked=\"false\" Priority=\"1\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"Default Paragraph Font\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text Indent\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"List Continue 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Message Header\"\/>   <w:LsdException Locked=\"false\" Priority=\"11\" QFormat=\"true\" Name=\"Subtitle\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Salutation\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Date\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text First Indent\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text First Indent 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Note Heading\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text Indent 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Body Text Indent 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Block Text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Hyperlink\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"FollowedHyperlink\"\/>   <w:LsdException Locked=\"false\" Priority=\"22\" QFormat=\"true\" Name=\"Strong\"\/>   <w:LsdException Locked=\"false\" Priority=\"20\" QFormat=\"true\" Name=\"Emphasis\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Document Map\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Plain Text\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"E-mail Signature\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Top of Form\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Bottom of Form\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Normal (Web)\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Acronym\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Address\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Cite\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Code\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Definition\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Keyboard\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Preformatted\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Sample\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Typewriter\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"HTML Variable\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Normal Table\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"annotation subject\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"No List\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Outline List 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Outline List 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Outline List 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Simple 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Simple 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Simple 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Classic 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Colorful 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Colorful 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Colorful 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Columns 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 7\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Grid 8\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 4\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 5\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 7\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table List 8\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table 3D effects 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table 3D effects 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table 3D effects 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Contemporary\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Elegant\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Professional\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Subtle 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Subtle 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Web 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Web 2\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Web 3\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Balloon Text\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" Name=\"Table Grid\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Table Theme\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Placeholder Text\"\/>   <w:LsdException Locked=\"false\" Priority=\"1\" QFormat=\"true\" Name=\"No Spacing\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 1\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" Name=\"Revision\"\/>   <w:LsdException Locked=\"false\" Priority=\"34\" QFormat=\"true\"    Name=\"List Paragraph\"\/>   <w:LsdException Locked=\"false\" Priority=\"29\" QFormat=\"true\" Name=\"Quote\"\/>   <w:LsdException Locked=\"false\" Priority=\"30\" QFormat=\"true\"    Name=\"Intense Quote\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"60\" Name=\"Light Shading Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"61\" Name=\"Light List Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"62\" Name=\"Light Grid Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"63\" Name=\"Medium Shading 1 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"64\" Name=\"Medium Shading 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"65\" Name=\"Medium List 1 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"66\" Name=\"Medium List 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"67\" Name=\"Medium Grid 1 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"68\" Name=\"Medium Grid 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"69\" Name=\"Medium Grid 3 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"70\" Name=\"Dark List Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"71\" Name=\"Colorful Shading Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"72\" Name=\"Colorful List Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"73\" Name=\"Colorful Grid Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"19\" QFormat=\"true\"    Name=\"Subtle Emphasis\"\/>   <w:LsdException Locked=\"false\" Priority=\"21\" QFormat=\"true\"    Name=\"Intense Emphasis\"\/>   <w:LsdException Locked=\"false\" Priority=\"31\" QFormat=\"true\"    Name=\"Subtle Reference\"\/>   <w:LsdException Locked=\"false\" Priority=\"32\" QFormat=\"true\"    Name=\"Intense Reference\"\/>   <w:LsdException Locked=\"false\" Priority=\"33\" QFormat=\"true\" Name=\"Book Title\"\/>   <w:LsdException Locked=\"false\" Priority=\"37\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" Name=\"Bibliography\"\/>   <w:LsdException Locked=\"false\" Priority=\"39\" SemiHidden=\"true\"    UnhideWhenUsed=\"true\" QFormat=\"true\" Name=\"TOC Heading\"\/>   <w:LsdException Locked=\"false\" Priority=\"41\" Name=\"Plain Table 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"42\" Name=\"Plain Table 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"43\" Name=\"Plain Table 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"44\" Name=\"Plain Table 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"45\" Name=\"Plain Table 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"40\" Name=\"Grid Table Light\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"Grid Table 1 Light\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"Grid Table 6 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"Grid Table 7 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"Grid Table 1 Light Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"Grid Table 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"Grid Table 3 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"Grid Table 4 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"Grid Table 5 Dark Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"Grid Table 6 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"Grid Table 7 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\" Name=\"List Table 1 Light\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\" Name=\"List Table 6 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\" Name=\"List Table 7 Colorful\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 1\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 2\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 3\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 4\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 5\"\/>   <w:LsdException Locked=\"false\" Priority=\"46\"    Name=\"List Table 1 Light Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"47\" Name=\"List Table 2 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"48\" Name=\"List Table 3 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"49\" Name=\"List Table 4 Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"50\" Name=\"List Table 5 Dark Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"51\"    Name=\"List Table 6 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" Priority=\"52\"    Name=\"List Table 7 Colorful Accent 6\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Mention\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Smart Hyperlink\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Hashtag\"\/>   <w:LsdException Locked=\"false\" SemiHidden=\"true\" UnhideWhenUsed=\"true\"    Name=\"Unresolved Mention\"\/>  <\/w:LatentStyles> <\/xml><![endif]--><!-- [if gte mso 10]>  <![endif]--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; &ldquo;A\u015eI&rdquo;LARLA; SA\u011eLIK MI, YOKSA HASTALIK MI A\u015eILANIYOR? &nbsp;&nbsp;&nbsp;&nbsp; Bir hastal\u0131\u011fa kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flamak veya bu hastal\u0131\u011f\u0131 tedavi etmek i&ccedil;in haz\u0131rlanan ve v&uuml;cuda kas, damar veya a\u011f\u0131z yoluyla verilen s\u0131v\u0131ya a\u015f\u0131 ismi verilir. A\u015f\u0131, zay\u0131flatma ad\u0131 verilen uygun bir sterilizasyonla hastal\u0131k yapma g&uuml;c&uuml; yok edilen bir mikrop maddesinden meydana gelmektedir. A\u015f\u0131n\u0131n yararlar\u0131 nelerdir? Uygun ve [&hellip;]<\/p>\n","protected":false},"author":104,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[98],"tags":[],"class_list":["post-5032","post","type-post","status-publish","format-standard","hentry","category-ozel-yazilar"],"_links":{"self":[{"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/posts\/5032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/users\/104"}],"replies":[{"embeddable":true,"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/comments?post=5032"}],"version-history":[{"count":0,"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/posts\/5032\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/media?parent=5032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/categories?post=5032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.millicozum.com\/mc\/wp-json\/wp\/v2\/tags?post=5032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}